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ABSTRACT
Glial cell line-derived neurotrophic factor (GDNF) and its family members neurturin 
(NRTN), artemin (ARTN) and persephin (PSPN) are growth factors, which are involved 
in the development, differentiation and maintenance of many neuron types. In addition, 
they function outside of the nervous system, e.g. in the development of kidney, testis 
and liver. GDNF family ligand (GFL) signalling happens through a tetrameric receptor 
complex, which includes two glycosylphosphatidylinositol (GPI)-anchored GDNF 
family receptor (GFRα) molecules and two RET (rearranged during transfection) 
receptor tyrosine kinases. Each of the ligands binds preferentially one of the four GFRα 
receptors: GDNF binds to GFRα1, NRTN to GFRα2, ARTN to GFRα3 and PSPN to 
GFRα4. The signal is then delivered by RET, which cannot bind the GFLs on its own, 
but can bind the GFL-GFRα complex. Under normal cellular conditions, RET is only 
phosphorylated on the cell surface after ligand binding. At least the GDNF-GFRα1 
complex is believed to recruit RET to lipid rafts, where downstream signalling occurs. 
In general, GFRαs consist of three cysteine-rich domains, but all GFRα4s except 
for chicken GFRα4 lack domain 1 (D1). We characterised the biochemical and 
cell biological properties of mouse PSPN receptor GFRα4 and showed that it has a 
signifi cantly weaker capacity than GFRα1 to recruit RET to the lipid rafts. In spite of 
that, it can phosphorylate RET in the presence of PSPN and contribute to neuronal 
differentiation and survival. Therefore, the recruitment of RET to the lipid rafts does not 
seem to be crucial for the biological activity of all GFRα receptors.
Secondly, we demonstrated that GFRα1 D1 stabilises the GDNF-GFRα1 complex 
and thus affects the phosphorylation of RET and contributes to the biological activity. 
This may be important in physiological conditions, where the concentration of the ligand 
or the soluble GFRα1 receptor is low. Our results also suggest a role for D1 in heparin 
binding and, consequently, in the biodistribution of released GFRα1 or in the formation 
of the GFL-GFRα-RET complex.
We also presented the crystallographic structure of GDNF in the complex with 
GFRα1 domains 2 and 3. The structure differs from the previously published ARTN-
GFRα3 structure in three signifi cant ways. The biochemical data verify the structure 
and reveal residues participating in the interactions between GFRα1 and GDNF, and 
preliminarily also between GFRα1 and RET and heparin. 
Finally, we showed that, the precursor of the oncogenic MEN 2B (multiple endocrine 
neoplasia type 2) form of RET gets phosphorylated already during its synthesis in the 
endoplasmic reticulum (ER). We also demonstrated that it associates with Src homology 
2 domain-containing protein (SHC) and growth factor receptor-bound protein (GRB2) in 
the ER, and has the capacity to activate several downstream signalling molecules.

1Neurotrophic factors inside 1. 
and outside of the nervous 
system
The development and maintenance of the 
nervous system is regulated by a great 
variety of molecules, including small 
secretory proteins called neurotrophic 
factors. The fi rst growth factor that was 
shown to stimulate growth and support 
the survival of neurons was the nerve 
growth factor NGF (Levi-Montalcini and 
Hamburger, 1951, Cohen et al., 1954). 
Subsequently, several other factors 
(discussed below) that can regulate 
survival and differentiation of nerve cells 
have been identifi ed. Some of these growth 
factors are also active in non-neuronal 
tissues. Because of the therapeutic 
potential of growth factors, the field of 
neurotrophic factor research has expanded 
fast.
In the early stages of nervous system 
development, more neurons are produced 
than are present in an adult individual. 
In normal development, during a period 
of programmed cell death, a significant 
part of developing neurons will die. This 
process seems to give adaptability to 
the nervous system: When an excess of 
neurons is produced, they are available 
for adaptive use during neuronal 
development (reviewed in Oppenheim, 
1991). The originally presented target-
derived neurotrophic factor hypothesis 
(Thoenen and Barde, 1980) suggested 
that the survival of each population of 
neurons strongly depends on a single 
neurotrophic factor supplied by its target 
fi eld and, without this factor, the neurons 
die by default. According to this model, 
neurotrophic factors are synthesised in 
limiting amounts so that only the required 
number of neurons have suffi cient access 
to the neurotrophic factor support to 
survive. Later, it has been recognised 
that, for many neuronal populations, 
the survival effect is regulated by a co-
operation of many neurotrophic factors 
(reviewed in Davies, 1996).
Most trophic factors in the central 
nervous system can be grouped into 
families based on their structural 
homology. The families of neurotrophins, 
neurokines and glial cell line-derived 
neurotrophic factor (GDNF) family 
ligands (GFLs) are named and classifi ed 
as neurotrophic factor families because 
their fi rst described and most prominent 
effects were neurotrophic. However, 
members of these families have later been 
shown to have important functions also 
outside of the nervous system. Moreover, 
several other factors classifi ed as merely 
growth factors have been shown to have 
also neurotrophic effects.
All  in al l ,  the concept of a 
neurotrophic factor is very obscure. 
First, some inorganic molecules can 
promote the survival of neurons: e.g. 
high potassium concentrations support 
the survival of chick sympathetic neurons 
(Por and Huttner, 1984), so it has to be 
decided whether the term neurotrophic 
factor can be used for any molecule or 
only proteins or peptides. Mitsumoto and 
Tsuzaka propose in their review (1999) 
that “neurotrophic factors are signalling 
proteins that enhance neuronal survival, 
maintenance and differentiation, but 
they also can increase neurite growth 
and neurotransmitter production”. This, 
however, leaves space for discussion of 
whether a factor should contribute to all 
of these functions in order to be defi ned 
as neurotrophic, or whether promoting 
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2one of them is enough. One question is 
also whether a neurotrophic factor has 
to be a protein secreted by other cells, or 
whether it can function within the same 
cell, or, for example, from the surface of a 
neighbouring cell.
Another set of criteria to define a 
neurotrophic factor by Barde (1988) 
includes four requirements: in order to be 
defi ned as a neurotrophic factor, a molecule 
must 1) keep alive vertebrate neurons that 
would die in the absence of the factor, 2) 
be present in the biologically active form, 
synthesised and secreted from the target 
tissue of those neurons that will be saved, 
3) be present in the target tissue in very 
small amounts and support the survival of 
a specifi c and limited set of neurons and 
4) affect the development or maintenance 
of neurons in vivo. In conclusion, the 
current view seems to be that the minimal 
requirements of a neurotrophic factor are 
that the factor is secreted from the target 
tissue of the neurons and has the ability 
to support the survival of a certain neuron 
population in vivo.
Classifi cation of neurotrophic 1.1 
factors
There are currently four main families 
of growth factors that, according to the 
classical view, are specifi c to the nervous 
system: neurotrophins, neurokines, the 
MANF (mesencephalic astrocyte-derived 
neurotrophic factor) family and GFLs. The 
classification is based on the homology 
in the amino acid sequences and the 
structures of the neurotrophic factors.
Neurotrophins and GFLs belong 
to a large superfamily of cysteine-knot 
growth factors, which also includes e.g. 
the transforming growth factor β (TGF-β) 
family of growth factors, human chorionic 
gonadotropin, platelet-derived growth 
factors and vascular endothelial growth 
factors (Butte 2001). All the members 
of this family contain a cystine knot that 
consists of three disulfide bonds. The 
neurotrophins form a non-covalently 
linked head-to-head dimer, whereas 
the monomers of GDNF and its family 
members are arranged head-to-toe and 
covalently linked by a disulfide bond. 
The three-dimensional structures of these 
factors are surprisingly similar in spite of 
their quite different amino acid sequences 
(Butte 2001). The structure of GFLs will 
be discussed in more detail later in this 
thesis.
Ciliary neurotrophic factor (CNTF) 
and most other neurokines are not cysteine-
knot proteins, but consist of four helices 
forming a bundle. In the original crystal 
structure (McDonald et al., 1995), CNTF 
seemed to be a dimer, but the authors note 
that this might be a crystallisation artefact. 
Later, it has been shown that CNTF exists 
primarily as a monomer, but significant 
dimer formation occurs at high protein 
concentrations (Narhi et al., 1997). MANF 
family members MANF and CDNF 
(conserved dopamine neurotrophic factor) 
are secreted proteins with eight conserved 
cysteine residues. The crystal structures 
of both MANF and CDNF were solved 
very recently and they do not resemble 
the structure of any known growth factor. 
In both proteins the N-terminal domain 
is a saposin-like lipid-binding domain 
and the C-terminal domain contains a 
CKGC disulphide bridge like reductases 
and disulphide isomerases (Parkash et al., 
2009).
Neurotrophins1.1.1 
The mammalian neurotrophin family 
includes nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), 
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3neurotrophin-3 (NT-3) and neurotrophin-
4/5 (NT-4/5). Neurotrophin signalling 
is critically involved in the development 
of the brain and nervous system, but 
neurotrophins also play a role at least in 
retinal, cochlear and heart development 
(Frade et al., 1999, Fritzsch et al., 1997, 
Tessarollo et al., 1997). Moreover, 
neurotrophins, and BDNF in particular, 
are essential in the maintenance and 
plasticity of the adult neurons and their 
connections (reviewed in Chao, 2003, 
McAllister et al., 1999 and Lykissas et al., 
2007). Neurotrophins are synthesised as 
large precursors, which are then processed 
to yield the pro-forms of neurotrophins 
and ultimately, the mature, neurotrophic 
proteins. The mature neurotrophins have 
a molecular weight of ~12-13 kDa and 
share about 50 % homology (Butte et al., 
2001). Interestingly, pro-forms of some 
neurotrophins have been found to have 
very different functions from the mature 
forms (Lee et al., 2001, Teng et al., 
2005). 
Neurokines1.1.2 
Neurokines, also called neuropoietic 
cytokines, or the CNTF-family, according 
to its best-characterised member, are small 
molecules that are structurally similar 
to cytokines and signal using common 
cytokine receptor components. CNTF was 
originally described as a growth factor that 
supports the survival of parasympathetic 
neurons from the chick ciliary ganglia 
(Adler et al., 1979). Later, it has been 
found to have trophic and differentiating 
effects on different types of peripheral 
and central neurons and glia, but most 
prominently it affects the survival of 
motoneurons (reviewed in Vergara and 
Ramirez, 2004). In addition to CNTF, 
well-known members of this family are 
interleukin 6 (IL-6), cardiotrophin 1 and 2, 
and leukaemia inhibitory factor (LIF). The 
actions of these cytokine family members 
on neurons are similar to CNTF’s effects 
in some cases, but have much broader 
actions throughout the rest of the body (Ip 
and Yancopoulos, 1996).
MANF family1.1.3 
The very recently found MANF family 
consists of MANF, which is originally 
known as ARMET (arginine-rich, mutated 
in early stage tumours), and a homologous 
protein, CDNF (Shridhar et al., 1996, 
Petrova et al., 2003, Lindholm et al., 
2007). MANF was described recently as 
a survival promoting factor for embryonic 
midbrain dopaminergic neurons in vitro 
(Petrova et al., 2003), and it is expressed 
widely in both the nervous system and 
non-neuronal tissues (Lindholm et al., 
2008). CDNF has been shown to function 
as a trophic factor for dopamine neurons 
in vivo and is expressed in the adult mouse 
heart, skeletal muscle and testis as well as 
in several neuronal cell types (Lindholm 
et al., 2007). In addition, CDNF and 
MANF have been suggested to inhibit ER 
stress-induced cell death (Apostolou et al., 
2008, Parkash et al., 2009). The receptors 
for MANF and CDNF are still unknown. 
Mammalian MANF and CDNF have an 
invertebrate homologue in Drosophila 
melanogaster, where this protein regulates 
the development of dopamine neurons 
(Palgi et al., 2009).
GDNF and its family ligands1.1.4 
GFL family members GDNF, neurturin 
(NRTN), artemin (ARTN) and persephin 
(PSPN) belong to the TGF-β superfamily 
and are involved in the development, 
differentiation and maintenance of 
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many neuron types (Airaksinen et al., 
1999). GDNF was first described as a 
neurotrophic factor that promotes the 
survival of midbrain dopaminergic neurons 
in vitro (Lin et al., 1993). This finding 
raised substantial interest because the 
symptomatic phases of Parkinson’s disease 
(PD) are characterised by degeneration 
of dopaminergic neurons in the midbrain 
which innervate the striatum (German et 
al., 1992).
Later, GDNF has been found to 
be a potent trophic factor for spinal 
motoneurons (Henderson et al., 1994) and 
for central noradrenergic neurons (Arenas 
et al., 1995), and to play a critical role 
also outside the nervous system, e.g. in 
kidney development and spermatogenesis 
(Moore et al., 1996, Pichel et al., 1996, 
Sánchez et al., 1996, Meng et al., 2000). 
GDNF is expressed widely in the central 
and peripheral nervous system (Schaar et 
al., 1993, Strömberg et al., 1993, Golden 
et al., 1998), but also in a variety of other 
tissues and cell types (Trupp et al., 1995, 
Suvanto et al., 1996, Golden et al., 1999)
The most common isoform of 
GDNF is synthesised as a 211 amino 
acid precursor form, whereas the mature, 
secreted form consists of only 134 amino 
acids and has a molecular weight of ~20 
kDa (Lin et al., 1993) (Figure 1). Both the 
secretion and proteolytic processing of 
GDNF are, however, quite poorly known. 
The precursors of some other neurotrophic 
factors, for example proNGF, have been 
shown to have other biological functions 
than the mature factors (Lee et al., 2001), 
so it can be speculated that also proGDNF 
and other proGFLs could have unexpected 
roles (Airaksinen and Saarma, 2002).
As is the case with a number of 
other neurotrophic factors, GDNF binds 
strongly to heparin (Lin et al., 1994, 
Alfano et al., 2007), which is thought to 
retain GDNF close to its site of secretion 
within the tissue, and thus raise its local 
concentration. At low concentrations, 
heparin protects GDNF from proteolytic 
modifi cation by an endoprotease (Rickard 
et al., 2003). Heparan sulphates, which 
are structurally related to heparin, are 
widely distributed on cell surfaces and 
in the extracellular matrix, and it has 
been claimed that GDNF signalling 
requires cell surface heparan sulphate 
glycosaminoglycans (Barnett et al., 2002, 
Davies et al., 2003). Davies et al. (2003) 
also report that low concentrations of 
exogenous heparin can block the neurite 
outgrowth induced in PC12 cells by 
GDNF and soluble GDNF family receptor 
α1 (GFRα1) protein. Similar results are 
reported by Ai et al. (2007), showing 
also that the activity of Sulfs, heparan 
sulphate modifying enzymes, decreases 
GDNF binding to heparan sulphates, 
promoting GDNF signalling. On the other 
hand, exogenous heparin has been shown 
to promote the activity of GDNF in the 
induction of tyrosine hydroxylase (TH) 
gene expression in neuroblastoma cells 
(Tanaka et al., 2002). Therefore, the role 
of heparan sulphates in GDNF signalling 
remains unclear. 
Neurturin
NRTN is structurally related to GDNF, 
and its mature form shows 42 % sequence 
similarity with it. NRTN was fi rst isolated 
on the basis of its ability to support 
the survival of sympathetic neurons in 
culture (Kotzbauer et al., 1996), and, like 
GDNF, it has been shown to promote 
the survival of dopaminergic neurons 
(Horger et al., 1998). Therefore, trials 
to protect dopaminergic neurons from 
extensive cell death have been carried out 
in various models of progressive PD, with 
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variable results (Rosenblad et al., 1999, 
Oiwa et al., 2002, Ceregene Press release 
26.11.2008).
NRTN has also been shown to support 
survival and proliferation of several other 
neuron populations in the central and 
peripheral nervous system (Kotzbauer et 
al., 1996, Klein et al., 1997, Heuckeroth 
et al., 1998, Rossi et al., 1999, Golden 
et al., 2003). Most importantly, NRTN 
regulates the development of most of 
the parasympathetic neurons (Rossi et 
al., 1999). In addition, NRTN promotes 
epithelial branching, can induce branch 
initiation in developing kidney (Davies 
et al., 1999), directs liver bud migration 
(Tatsumi et al., 2007) and contributes to 
retinal function (Brantley et al., 2008). 
The prominent expression of NRTN in the 
gut, prostate, testicle and oviduct of adult 
mice also suggest some functions in these 
tissues (Golden et al., 1999).
The pre-pro-form of NRTN consists 
of 195 amino acids and it is cleaved to 
generate a 100 residue mature protein, 
which has a molecular mass of ~12 kDa 
(Kotzbauer et al., 1996) (Figure 1). 
Mature NRTN has also been shown to 
bind heparin, even with a higher affi nity 
than GDNF (Alfano et al., 2007).
Artemin
Artemin is a survival and growth factor 
for sympathetic and sensory neurons in 
vitro (Baloh et al., 1998, Enomoto et al., 
2001), and a potent neuroprotective factor 
for the rodent nigrostriatal DA neurons in 
vivo (Rosenblad et al., 2000). The ARTN 
sequence is more similar to the NRTN 
and PSPN sequences than to the GDNF 
sequence (Baloh et al. 1998). ARTN 
mRNA is expressed in brain and various 
other tissues, but the expression levels 
are highest in peripheral tissues including 
prostate, placenta, pancreas, heart and 
kidney (Masure et al., 1999). ARTN has 
been found to regulate sensory function 
(Wang et al., 2008) and is therefore being 
considered for the treatment of chronic 
pain (Gardell et al., 2003).
Like GDNF and NRTN, ARTN is also 
synthesised as a pre-pro-form which is 
processed to form a mature 113 amino acid 
protein with a molecular weight of ~12 
kDa (Figure 1). Like GDNF and NRTN, 
ARTN has also been found to strongly 
bind heparin (Alfano et al., 2007).
Persephin
Persephin is related to other GFLs and 
shows about 40 % sequence identity to 
GDNF and NRTN. PSPN promotes the 
survival of ventral midbrain dopaminergic 
neurons in culture, supports the survival 
of motor neurons in culture and in vivo 
after sciatic nerve axotomy and, like 
GDNF, promotes ureteric bud branching 
in vitro (Milbrandt et al., 1998, Åkerud 
et al., 2002). Moreover, PSPN promotes 
the survival of embryonic basal forebrain 
cholinergic neurons in vitro (Golden et 
al., 2003). However, PSPN has not been 
found to support any peripheral neurons 
that have been examined. The expression 
of PSPN seems to be quite wide, but the 
detected mRNA levels are very low in 
most tissues (Milbrandt et al., 1998, Jaszai 
et al., 1998, Lindfors et al., 2006).
In addition, PSPN has been shown to 
promote both survival and neuritogenesis 
of midbrain dopamine neurons and thus 
it has been suggested that PSPN, like 
GDNF and NRTN, might have therapeutic 
potential in the treatment of Parkinson’s 
disease (Åkerud et al., 2002). In addition, 
future therapeutic approaches may involve 
the use of PSPN in the treatment of stroke 
(Tomac et al., 2002). 
6The pre-pro-form of PSPN is 156 
amino acids long and is cleaved to 
produce a 96 amino acids long mature 
protein with a molecular weight of 
10-12 kDa (Milbrandt et al., 1998) 
(Figure 1). Differently from other GFLs, 
PSPN is not able to bind to heparin and 
heparan sulphates (M. Bespalov, personal 
communication).
2.  Neurotrophic factor receptors
Receptors are proteins that bind their 
specifi c ligands and mediate the ligand’s 
messages of growth, differentiation, 
apoptosis or other functions. According 
to the target-derived neurotrophic factor 
hypothesis, neurotrophic factors are 
synthesised in limiting amounts so that 
only a limited number of neurons can 
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Figure 1. Sequence alignment of the GFLs. GDNF, ARTN and PSPN sequences are rat 
sequences and NRTN is the mouse sequence (rat NRTN sequence is not available). Regions with 
high degree of sequence similarity are shown bold (according to MultAlin based on the algorithm 
described in Corpet, 1988). Structural and functional properties are highlighted as follows: 
Single underline; α-helix according to the crystal structure from Eigenbrot and Gerber, 1997 
(GDNF) and Silvian et al., 2006 (ARTN). Double underline; heparin binding sequence/residue 
according to the experimental data from Alfano et al., 2007 (GDNF) and Silvian et al., 2006 
(ARTN). Purple; cysteine residue thought to participate in the intramolecular cysteine bridges. 
Green; signal peptide (according to Uniprot). Blue; propeptide (according to Uniprot). Pink; 
residues interacting with GFRα according to Wang et al., 2006 (ARTN) and IV (GDNF).
GDNF    MKLWDVVA V--CLVLLHT ASAFPLPAGK RLLEAPAEDH SLGHRRVPFA 
NRTN                  MRRWK AAALVSLICS SLLS--VWMC QEGLLLGHRL 
ARTN  MELGLGEPTA LSHCLRPRWQ PALWPTLAAL ALLSSVTEAS LDPMSRSPAS 
PSPN
GDNF  LTSDSNMPED YPDQFDDVMD FIQATIKRLK RSPDKQAAAL PRRERNRQA- 
NRTN  GPALAPLRRP PRTL--DARI ARLAQYRALL ------QGAP DAVELRELSP 
ARTN  RDVPSPVLAP PTDYLPGGHT AHLCSERALR PPPQSPQPAP PPPGPALQSP 
PSPN           M AAGRLRILFL LLLSLHLGLG WVLDLQEA-- PAADELSSGK 
GDNF  -AAASPENSR GKGRRGQRGK N---RGCVLT AIHLNVTDLG LGYETKEELI
NRTN  WAARIPGPRR RAGPRRRRAR P-GARPCGLR ELEVRVSELG LGYTSDETVL
ARTN  PAALRGARAA RAGTRSSRAR ATDARGCRLR SQLVPVSALG LGHSSDELIR
PSPN  MAETGRTWKP HQGNNNVRLP RALPGLCRLW SLTLPVAELG LGYASEEKII
GDNF FRYCSGSC-E AAETMYDKIL KNLSRSRRLT ----SDKVGQ ACCRPVAFDD
NRTN FRYCAGAC-E AAIRIYDLGL RRLRQRRRVR R---ERARAH PCCRPTAYED
ARTN FRFCSGSC-R RARSPHDLSL ASLLDAGALR SPPGSRPISQ PCCRPTRYE-
PSPN FRYCAGSCPQ EVRTQHSLVL ARLRGQGRAH --------GR PCCQPTSYAD
GDNF  DLSFLDDSLV YHILRKHSAK RCGCI
NRTN  EVSFLDVHSR YHTLQELSAR ECACV
ARTN  AVSFMDVNST WRTVDHLSAT ACGCLG
PSPN  -VTFLDDHHH WQQLPQLSAA ACGCGG
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get enough of the neurotrophic factor 
support to survive. To avoid programmed 
cell death, neurons have to compete for 
the scarce quantities of trophic factors. 
Therefore, it is crucial that neurons express 
receptors that bind neurotrophic factors 
with high affi nity and specifi city.
2.1  Receptors of neurotrophins
The majori ty of  t rophic act ions 
of neurotrophins are mediated by 
tropomyosin-related kinase (Trk)-type 
tyrosine kinase receptors: NGF signals 
via the TrkA receptors, BDNF and NT-
4/5 signal via the TrkB receptors, and 
NT-3 signals via the TrkC receptors (Chao 
and Hempstead, 1995). Trk receptors are 
transmembrane proteins that span the 
membrane once and contain a heavily 
glycosylated extracellular domain, as 
well as a cytoplasmic domain consisting 
of a tyrosine kinase (TK) domain. The 
extracellular domain of each of the Trk 
receptors consists of a cysteine-rich 
cluster followed by three leucine-rich 
repeats, another cysteine-rich cluster 
and two immunoglobulin-like domains. 
These domains determine principally the 
affi nity and specifi city of binding of the 
neurotrophin (Pérez et al., 1995, Urfer et 
al., 1995, Ultsch et al., 1999).
Upon ligand binding, the tyrosines 
residing in the autoregulatory loop 
of Trk receptor TK domain become 
phosphorylated. This further leads to the 
phosphorylation and activation of the 
other intracellular tyrosine residues. The 
phosphorylated tyrosines function as 
docking sites for a number of cytoplasmic 
adaptor proteins, leading to the activation 
of various intracellular signalling 
cascades important for neuronal survival, 
differentiation and plasticity (reviewed by 
Reichardt, 2006). Intracellularly truncated 
forms, and thus catalytically inactive forms 
of TrkB and TrkC receptors, also exist. 
Many of the functions of these receptors 
are unknown, but they might spatially 
restrict the actions of neurotrophins 
(neurotrophin scavengers) and inhibit Trk 
receptor signalling (dominant negative 
action) (Eide et al., 1996, Haapasalo et al., 
2001). 
Each neurotrophin is also capable 
of interacting with the low affinity p75 
receptor, which belongs to the tumour 
necrosis factor receptor superfamily 
(TNFR) (Chao and Hempstead, 1995). 
The p75 receptor is widely expressed 
in the developing central and peripheral 
nervous system during the period of 
synaptogenesis and developmental cell 
death (Davies, 1991). The p75 receptor 
is a type I transmembrane protein with 
a molecular weight of ~75 kDa and 
consists of an extracellular domain that 
includes four cysteine-rich motifs, a single 
transmembrane domain and a cytoplasmic 
domain. The intracellular domain of p75 
lacks catalytic activity, but contains a 
death domain motif similar to those found 
in other members of the TNFR family 
and their downstream targets (Liepinsh 
et al., 1997, He and Garcia 2004). One 
established function of p75 is indeed to 
promote cell death (Hempstead, 2002, 
Miller and Kaplan, 2001). However, 
TrkA-induced survival signalling protects 
neurons from p75-mediated developmental 
cell death (Majdan et al . ,  2001). 
Depending on the cellular context, the p75 
receptors can also modulate the signalling 
of Trk receptors (Hempstead et al., 1991, 
Bibel et al., 1999, Esposito et al., 2001) or 
promote either atrophic or trophic cellular 
actions (Blöchl and Blöchl, 2007).
The p75 receptor-mediated cellular 
responses to mature neurotrophins are 
generally weak, but, interestingly, pro-
8neurotrophins preferentially activate 
p75 receptors and thereby produce very 
different changes on neuronal functions 
compared to the mature neurotrophins 
(Lee et al., 2001, Teng et al., 2005). The 
authors in the study by Lee et al. (2001) 
stated that proNGF binds to p75 with 
a higher affinity than the mature NGF. 
However, Nykjaer et al. (2004) showed 
that actually the lack of processing reduces 
the affi nity of proNGF for both p75 and 
TrkA, but increases the affi nity for a p75 
co-receptor, sortilin. Thus, sortilin and p75 
co-operate in mediating proNGF-induced 
cell death. Like p75-defi cient mice, sortilin 
1-defi cient mice show reduced neuronal 
apoptosis (Jansen et al., 2007). 
In contrast, the binding of mature 
NGF to p75 and TrkA is not signifi cantly 
affected by sortilin (Nykjaer et al., 
2004). Later, it has also been shown that 
proBDNF is secreted from mouse neurons 
(Yang et al., 2009) and it binds to a 
receptor complex formed by p75/sortilin 
leading to apoptosis (Teng et al., 2005).
Neurotrophins bind as dimers to 
p75 receptors and Trk receptor family 
members. He and Garcia (2004) have 
reported that NGF binding to p75 results 
in a conformational change in NGF that 
alters the structure of the opposite side of 
the NGF dimer, preventing the binding of 
one NGF dimer to another p75 monomer. 
However, in another study (Aurikko et al., 
2005), the p75/NGF complex was found 
to have a 2:2 stoichiometry. The authors 
of this study propose the discrepancy to be 
due to the absence of glycosylation of p75 
in He and Garcia (2004). 
2.2  Receptors of neurokines
CNTF, LIF, IL-6 and many other cytokines 
belong to a family called interleukin-6-
type cytokines. Members of this family 
bind to receptors that can be classified 
in the non-signalling α-receptors – IL-6 
receptor α, IL-11 receptor α, and CNTF 
receptor α – and the signal transducing 
receptors – glycoprotein 130 (gp130), 
LIF receptor (LIFR), and oncostatin M 
receptor (OSMR). The signal transducing 
receptors become tyrosine phosphorylated 
in response to cytokine stimulation and 
mediate the signal into the cell (Davis 
et al., 1993a). Each of the IL-6-type 
cytokines recruits by ligand binding at 
least one gp130.
IL-6, IL-11 and CNTF first bind 
specifi cally to their respective α receptors. 
This binding induces the recruitment 
of two signalling receptors that are not 
associated at the cell surface before 
binding to the ligand–α receptor complex 
(Vergara and Ramirez, 2004). IL-6 and 
IL-11 signal through gp130 homodimers, 
whereas other IL-6 type cytokines signal 
through heterodimers of gp130 and LIFR, 
or gp130 and OSMR. LIF and oncostatin 
M bind their signalling receptors directly 
without an α receptor (Heinrich et al., 
2003). Upon binding of the ligand, 
the intracellular domains of signalling 
receptors become associated with a variety 
of signalling molecules, for example JAK 
(Janus kinase) tyrosine kinase family 
members, and activate them. 
Non-signalling receptors, described 
above, are homologous and thus form a 
family of cytokine receptor family type 
1. The extracellular region of members of 
this receptor family contains combinations 
of cytokine domains, fibronectin III-
like domains and, in some cases, also 
immunoglobulin-like domains. All 
these cytokine receptors have a single 
22–28 amino acid transmembrane 
domain and an intracellular domain, 
except for CNTF receptor (CNTFRα) 
(Vergara and Ramirez, 2004). CNTF 
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receptor is anchored to the membrane by 
a glycosylphosphatidylinositol (GPI)-
anchor. Due to its GPI-linkage, it can be 
cleaved by phosphatidylinositol-specifi c 
phospholipase C (PI-PLC) to produce 
a soluble and functional form of the 
receptor (Davis et al., 1993b). Soluble 
forms of other cytokine receptors can be 
produced by alternative splicing or limited 
proteolysis of membrane bound proteins 
(Rose-John and Heinrich 1994).
2.3  Receptors of GDNF family 
ligands
The best-known GFL signalling happens 
through a tetrameric receptor complex, 
which includes two GFRα molecules and 
two RET (rearranged during transfection) 
receptor tyrosine kinases (Takahashi et al., 
1985, Durbec et al., 1996a, Trupp et al., 
1996). In this model of GFL signalling, 
GPI-anchored receptors GFRα1-4 bind 
their ligands GDNF, NRTN, ARTN and 
PSPN, respectively, but cannot mediate 
the signal through the cell membrane. 
The signal is then delivered by the 
transmembrane receptor RET that cannot 
bind GFLs on its own, but can bind the 
GFRα/GFL complex (Figure 2).
In several cell and tissue types GFRαs 
are expressed at high levels, whereas RET 
is undetectable (Trupp et al., 1997, Golden 
et al., 1999). This enigma could in theory 
be explained by GFL signalling through 
GFRα alone, or in association with some 
other receptor than RET. An alternative 
possibility is that the receptor complexes 
would be formed between RET and GFRα 
receptor from adjacent cells, or that the 
GFL-responsive cells would express RET 
with the co-receptor supplied in a soluble 
form. There is indeed evidence that these 
signalling modes are used by GFLs: RET 
can be activated by GFRα1 molecules 
presented on the membrane of adjacent 
cells, which themselves do not express 
RET. Also released GFRα1 is capable of 
mediating GDNF signalling (Paratcha 
et al., 2001). When GFRα1 is present on 
both the cell surface and in a soluble form, 
it has been suggested that interactions 
between these forms of GFRα1 could act 
to potentiate the effects of GDNF (Worley 
et al., 2000). It has been shown that the 
neural cell adhesion molecule (NCAM) 
can function as a signalling receptor for 
GFLs (Paratcha et al., 2003). In addition, 
GDNF has been found to be able to 
signal through the Met receptor tyrosine 
kinase (Popsueva et al., 2003). It has 
also been shown that GFLs and GFRαs 
may have cellular functions independent 
of RET or NCAM, such as cell adhesion 
(Ledda et al., 2007), and regulation of 
differentiation and migration of cortical 
GABAergic neurons (Pozas and Ibáñez, 
2005). However, these RET-independent 
signalling mechanisms are still relatively 
poorly known and this thesis concentrates 
on GDNF signalling via RET. 
2.3.1 GFRα receptors
There are four different GFRα receptors: 
GFRα1 (Jing et al., 1996, Treanor et 
al., 1996), GFRα2 (Baloh et al., 1997, 
Buj-Bello et al., 1997, Jing et al., 1997, 
Klein et al., 1997, Suvanto et al., 1997), 
GFRα3 (Jing et al., 1997, Baloh et al., 
1998, Masure et al., 1998, Naveilhan et 
al., 1998, Nomoto et al., 1998, Trupp et 
al., 1998, Widenfalk et al., 1998, Worby 
et al., 1998) and GFRα4 (Thompson et 
al., 1998, Masure et al., 2000, Lindahl et 
al., 2000). The tissue expression pattern 
of GFRα receptors is very similar to their 
corresponding ligands, and each GFL 
seems to regulate the mRNA expression 
of its cognate co-receptor (Airaksinen 
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et al., 1999, Taraviras et al., 1999). 
GFL knockouts and their corresponding 
GFRα knockouts also show very similar 
phenotypes, which suggests a specific 
pairing in vivo (Airaksinen et al., 1999).
GFRα receptors are GPI-linked 
cell  surface proteins that lack a 
cytoplasmic domain capable of mediating 
transmembrane signalling. The length of 
the unprocessed form of rat GFRα1 is 468 
amino acids, of which the secretory and 
GPI-anchor mediating signals are removed 
(Jing et al., 1996) (Figure 3). In general, 
the lengths of all GFRα receptors are 
around 400 amino acids, and they contain 
three putative N-glycosylation sites. The 
predicted molecular weight of GFRα1 in 
the absence of glycosylation is about 47 
kDa (Jing et al., 1996).
Although GFL structures have striking 
resemblance to structures of several TGF-β 
family proteins (Daopin et al., 1993, 
Eigenbrot and Gerber, 1997, Silvian et 
al., 2006), GFRα receptors have very little 
in common with the receptors of TGF-β 
family members. GFRα receptors also 
lack many of the domains most commonly 
present in other receptors, such as leucine 
repeats, immunoglobulin-like domains, 
and fi bronectin-like domains (Scott and 
Ibáñez, 2001).
GFRα receptors are rich in cysteine 
with an unusual conserved spacing of 
these residues (Jing et al., 1996) (Figure 
3). In general, GFRα receptors consist 
of three homologous cysteine-rich 
domains (numbered 1-3 starting from 
the N-terminus). Domains 2 and 3 are 
located very closely, whereas domain 1 is 
separated from domain 2 by a quite long 
and flexible hinge region (Leppänen et 
al., 2004). Domains 2 and 3 are present 
in all GFRαs, but all GFRα4s except for 
chicken GFRα4 lack domain 1 (Lindahl et 
al., 2000, Masure et al., 2000, Lindahl et 
al., 2001).
GFRα receptors are initially linked 
to the plasma membrane from their 
C-terminus with GPI-anchors, but these 
anchors can be cleaved to generate 
soluble GFRαs. Soluble GFRα1 is 
able, together with GDNF, to induce 
RET phosphorylation in cells that do 
not express GFRα1 (Jing et al., 1996). 
Figure 2. Components of GFL–GFRα–RET complexes. GFL signalling happens through a 
tetrameric receptor complex, which includes two GPI-anchored GFRα molecules and two RET 
receptor tyrosine kinases. In the upper part of the fi gure only one RET and one GFRα receptor 
are shown. Each of the ligands binds preferentially one of the four GFRα receptors. The complete 
structure of the GFL2-GFRα2-RET2 complex has not been solved, but to illustrate the activated 
receptor complex, known and predicted structures of GFLs, GFRαs and RET have been used. 
Images of RET extracellular domain, NRTN, PSPN, and GFRα2 and GFRα4 are generated by 
homology modelling. NRTN and PSPN images are based on the GDNF crystal structure. GFRα1 
and GFRα3 models are based on the crystal structure of GFRα1 and the structure of the ARTN-
GFRα3 complex, respectively (Wang et al., 2006 and IV). RET cadherin-like domains (CLD, 
blue) and cysteine-rich domain (CRD, blue line) are modelled using E-cadherin and the laminin 
γ1 chain, respectively (Söding et al., 2005). RET intracellular domain models are based on the 
crystal structure of the RET kinase domain (Knowles et al., 2006). Calcium ions (yellow circle in 
the lower fi gure) are necessary for RET signalling. Modifi ed from Bespalov and Saarma, 2007.
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GFR?1              MFLATLYFA LPLLDLLMSA EVSGG-DRLD CVKASDQCLK
GFR?2   MILANAFCL FFFLDETLRS LASPSSPQGS ELHGWRPQVD CVRANELCAA 
GFR?3  MGLSWSPRPP LLMILLLVLS LWLPLGAGNS LATENRFVNS CTQARKKCEA 
GFR?4
GFR?1  EQSCSTKYRT LRQCVAGKET NFSLTSGLEA KDECRSAMEA LKQKSLYNCR
GFR?2  ESNCSSRYRT LRQCLAGRDR NTML-----A NKECQAALEV LQESPLYDCR 
GFR?3  NPACKAAYQH LGSCTSSLSR PLPLEESA-M SADCLEAAEQ LRNSSLIDCR 
GFR?4
GFR?1  CKRGMKKEKN CLRIYWSMYQ SL-QGNDLLE DSPYEPVNSR LSDIFRAVPF 
GFR?2  CKRGMKKELQ CLQIYWSIHL GLTEGEEFYE ASPYEPVTSR LSDIFRLASI 
GFR?3  CHRRMKHQAT CLDIYWTVHP ARSLGDYELD VSPYE----- --DTVTSKPW 
GFR?4                                               MAHCMESAL 
GFR?1  ISDVFQQVEH ISKGNNCLDA AKACNLDDTC KKYRSAYITP CTTSMS-NEV
GFR?2  FSGTGADPVV SAKSNHCLDA AKACNLNDNC KKLRSSYISI CNREISPTER
GFR?3  KMNLSKLNML KPDSDLCLKF AMLCTLHDKC DRLRKAYGEA CS-----GIR
GFR?4  LLLLLLGSAS FTDGNRCVDA AEACTADERC QQLRSEYVAR CLGRAAPGGR
GFR?1  -----CNRRK CHKALRQFFD KVPAKHSYGM LFCSC--RDI ACTERRRQTI
GFR?2  -----CNRRK CHKALRQFFD RVPSEYTYRM LFCSC--QDQ ACAERRRQTI
GFR?3  -----CQRHL CLAQLRSFFE KAAESHAQGL LLCPCAPEDA GCGERRRNTI
GFR?4  PGPGGCVRSR CRRALRRFFA RGPPALTHAL LFCGC--EGS ACAERRRQTF
GFR?1  VPVCSY--EE RERPNCLSLQ DSCKTNYICR SRLADFFTNC QPESRSVSNC
GFR?2  LPSCSY--ED KEKPNCLDLR SLCRTDHLCR SRLADFHANC RASYRTITSC 
GFR?3  APSCAL--PS -VTPNCLDLR SFCRADPLCR SRLMDFQTHC HP--MDILGT 
GFR?4  APACAFSGPG LVPPSCLEPL ERCERSRLCR PRLLAFQASC APAPGSRDRC 
GFR?1  LKENYADCLL AYSGLIGTVM TPNYVDSS-- SLSVAPWCDC SNSGNDLEDC
GFR?2  PADNYQACLG SYAGMIGFDM TPNYVDSNPT GIVVSPWCNC RGSGNMEEEC
GFR?3  CATEQSRCLR AYLGLIGTAM TPNFISKVNT TVALS--CTC RGSGNLQDEC
GFR?4  PEEGGPRCLR VYAGLIGTVV TPNYLDNV-- SARVAPWCGC AASGNRREEC
GFR?1  LKFLNFFKDN TCLKNAIQAF GNGSDVTMWQ PAPPVQTTTA TTTTAFRVKN 
GFR?2  EKFLKDFTEN PCLRNAIQAF GNGTDVNMSP KGPTFSATQA PRVEKTPSLP 
GFR?3  EQLERSFSQN PCLVEAIAAK MRFHRQLFSQ DWADSTFSVV QQQNSNPALR 
GFR?4  EAFRKLFTRN PCLDGAIQAF DSLQPSVLQD QTAGCCFPRV SWLYALTALA 
GFR?1  -KPLGPAGSE NEIPTHVLPP CANLQAQKLK SNVSGSTHLC LSDSDFGKDG 
GFR?2  -DDLSDSTS- --LGTSVITT CTSIQEQGLK ANNSKELSMC FTELTTNISP 
GFR?3  LQPRLPILSF SILPLILLQT LW
GFR?4  LQALL
GFR?1  LAGASSHITT KSMAAPPSCS LSSLPVLMLT ALAALLSVSL AETS 
GFR?2  GSKKVIKLYS GSCRARLSTA LTALPLLMVT LA
GFR?3
GFR?4
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In vivo soluble GFRα1 is released by 
enteric nervous system (ENS) neurons, 
neuronal cells, Schwann cells and injured 
sciatic nerve. It has been shown that RET 
stimulation by soluble GFRα1 potentiates 
downstream signalling, neurite outgrowth 
and neuronal survival (Paratcha et al., 
2001). It has also been suggested that 
alternative splicing could produce soluble 
GFRα4, but so far there is in vivo evidence 
only at mRNA level (Lindahl et al., 2001). 
However, there is evidence that soluble 
GFRα4 can associate in vitro with, and 
induce, phosphorylation of RET (Yang et 
al., 2007).
2.3.2 RET receptor tyrosine kinase
RET is a receptor tyrosine kinase (RTK) 
superfamily member that can function as a 
growth factor receptor or as an oncogenic 
protein. RET is expressed during vertebrate 
development in the developing excretory 
system, in the peripheral nervous system 
(PNS), and in motor and catecholaminergic 
neurons of the central nervous system 
(CNS) (Pachnis et al., 1993, Avantaggiato 
et al., 1994, Durbec et al., 1996b). In 
adult humans, RET is expressed at least in 
several neuronal cell types and chromaffi n 
cells of the adrenal medulla (Nakamura et 
al., 1994). In addition, RET is expressed 
in human tumours of neural crest origin 
(Santoro et al., 1990). RET dysfunction is 
connected to several congenital diseases, 
which will be discussed later in this thesis. 
It is also possible that RET can function 
in the absence of GDNF as a dependence 
receptor that induces apoptosis (Bordeaux 
et al., 2000) and thus, in some conditions, 
prevent tumour growth (Cañibano et al., 
2007).
Under normal circumstances, RET 
requires GPI-anchored co-receptors 
for ligand binding and activation. The 
current view is that RET is synthesised 
as a non-phosphorylated monomer, which 
can get into contact with its ligands and 
co-receptors only at the cell surface. 
RET harbours 12 putative N-linked 
glycosylation sites. The N-linked core 
glycosylation of RET takes place in the 
ER, and the molecular weight of RET 
initially increases from approximately 120 
kDa to 150 kDa (Takahashi et al., 1991). 
Further modification of glycosylation 
takes place in the Golgi apparatus and the 
molecular weight of mature RET is about 
170 kDa.
Due to alternative splicing of the 
RET primary transcript, RET is expressed 
as several isoforms (Tahira et al., 1990, 
Lorenzo et al., 1995, Ivanchuk et al., 
1997). The two best-studied and clearly 
most abundant isoforms differ in their 
C-termini. They share the fi rst N-terminal 
1063 amino acids, but the tail is different: 
The short isoform (RET9) has a C-terminal 
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Figure 3. Sequence alignment of the GFRαs. GFRα1 sequence is the rat sequence (used in this 
work) and GFRα2-4 sequences are mouse sequences (rat NRTN and rat ARTN sequences are 
not available). Regions of high degree of sequence similarity are shown in bold (according to 
MultAlin based on the algorithm described in Corpet, 1988). Structural and functional properties 
are highlighted as follows: Single underline; GFRα1 domain 1 (according to Leppänen et al., 
2004). Thick underline; GFRα1 domain 2 (according to the crystal structure, Leppänen et al., 
2004). Double underline; GFRα1 domain 3 (according to the crystal structure, Leppänen et 
al., 2004). Green; signal peptide (according to Uniprot). Blue; GPI-anchor signal sequence 
(according to Uniprot). Pink; residues interacting with GFL according to Wang et al., 2006 
(GFRα3) and IV (GFRα1).
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tail of nine amino acids and the whole 
protein consists thus of 1072 amino acids. 
The long isoform of RET (RET51) has a 
tail of 51 amino acids and it contains thus 
in total 1114 amino acids (Tahira et al., 
1990, Lorenzo et al, 1995). 
RET isoforms are differentially 
expressed in mouse embryos and in adult 
mice (Lee et al., 2003), and it has been 
shown by RT-PCR that in mouse tissues 
RET9 is predominantly expressed (Yoong 
et al., 2005). RET9 has been shown to be 
critical for the development of the mouse 
kidney and the enteric nervous system 
(de Graaff et al., 2001). On the other 
hand, RET51, but not RET9, is required 
for the metabolism and growth of mature 
rat sympathetic neurons (Tsui-Pierchala 
et al., 2002a) and may contribute more 
signifi cantly to the tumour development 
associated with multiple endocrine 
neoplasia 2 (MEN 2) than RET9 (Asai et 
al., 1996).
The biochemical differences which 
account for these functional differences 
between these isoforms are only partly 
known. Interestingly, Tyr1062, which is 
phosphorylated during the RET activation 
process and functions as an important 
docking site for adaptor proteins, is located 
right next to the last C-terminal residue 
that is common for both isoforms. It has 
indeed been suggested that the distinct 
activities of RET9 and RET51 result from 
the differential regulation of Y1062 by 
C-terminal fl anking sequences (Wong et 
al., 2005). In addition, RET51 also has 
two additional tyrosine residues, Tyr1090 
and Tyr1096, which may participate in 
signalling events. The two isoforms of 
RET interact differently with adapter 
proteins like Src homology 2 domain-
containing protein (SHC), growth factor 
receptor-bound protein 2 (GRB2) and 
Enigma (Lorenzo et al., 1997, Alberti et 
al., 1998, Borrello et al., 2002). Activated 
RET51 associates more strongly than 
RET9 with the ubiquitin ligase Cbl, which 
leads to faster turnover of RET51 (Scott et 
al., 2005).
3.  The GFL-GFRα-RET complex
The signal of GFLs is delivered into the 
cell by RET receptor tyrosine kinase, with 
the help of GFRαs that bind the GFL. 
These componets form the signalling 
complex on the cell surface. The GFL-
GFRα-RET complex is assumed to consist 
of a disulphide-linked GFL dimer and two 
GFRα molecules bound to two molecules 
of RET. According to the original model, 
the initial event of GDNF-GFRα-RET 
complex formation is the binding of 
dimeric GDNF to GFRα1, in either 
monomeric or dimeric form. The GDNF-
GFRα1 complex then interacts with 
two RET molecules, thereby inducing 
their homodimerisation and tyrosine 
autophosphorylation (Jing et al., 1996). It 
is believed that also other GFL members 
interact with their cognate co-receptors 
and activate RET in a similar manner to 
GDNF.
However, clear and direct evidence 
of the complex formation has not been 
established. It is possible that GFL and 
GFRα form together a binding surface for 
RET, or that the binding of GFL changes 
the conformation of GFRα, creating thus 
a binding site for RET. In these models, 
GFRα and RET would not bind each other 
without the presence of GFLs. On the 
other hand, it is possible that monomeric 
GFRα and monomeric RET form a pre-
associated complex to which GFLs can 
then bind. The formation of the complex 
could happen in three different ways 
(Figure 4): 1) GFL2 (GFL homodimer) 
binds fi rst to GFRα, this complex recruits 
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a second co-receptor, and the GFL2-
GFRα2 complex recruits two molecules 
of RET. Alternatively, after binding of 
GFL2 to GFRα, one molecule of RET is 
recruited, and then a second monomeric 
GFRα and RET are recruited to the GFL2-
GFRα-RET complex. 2) GFL2 binds to a 
pre-associated GFRα-RET heterodimer 
and recruits another GFRα-RET pair. 3) 
Upon GFL2 binding, a pre-associated 
GFRα2-RET2 het erotetramer undergoes a 
conformational change and gets activated.
Different views on the structure and 
kinetics of the GFL/GFRα/RET complex 
have been proposed on the basis of partially 
controversial results of the interactions 
between the complex members. Jing et al. 
(1996) proposed that RET is not involved 
in the initial binding of GDNF to the 
complex. However, it has been shown that 
these two components can be cross-linked 
in the presence of GFRα1, which indicates 
that these two molecules are at least in 
close proximity in the complex (Trupp et 
al., 1996, Amoresano et al., 2005). There 
is also evidence of pre-association between 
GFRα1 or GFRα2, and RET (Sanicola et 
al., 1997, Treanor et al., 1996). The fact 
that some GDNF mutants with impaired 
ability to interact with GFRα1 can still 
activate RET in the presence of GFRα1 
(Eketjäll et al., 1999) suggests that, either 
there is a preformed GFRα1/RET complex 
that has a higher affi nity to GDNF than 
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Figure 4. Putative mechanisms of GFL–GFRα–RET receptor complex activation. Only the 
extracellular parts of RET are shown. The cadherin-like domains (CLD) of RET are red and the 
cysteine-rich domain (CRD) is green. GFL2 is grey and GFRα receptor blue. The formation of 
the complex could happen in three different ways described in the text. The model of the GFL2-
GFRα2-RET2 complex shown in the lower part of the fi gure is loosely based on the results of 
Kjaer and Ibáñez, 2003, but also other models have been proposed. Modifi ed from Bespalov and 
Saarma, 2007.
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GFRα1 alone, or then RET just stabilises 
the GDNF/GFRα complex. In addition, 
Cik et al. (2000) found a high-affinity 
GDNF-binding site on GFRα1 only in the 
presence of RET. Yet Tansey et al. (2000) 
report that in their assays RET does not 
co-immunoprecipitate with GFRα co-
receptors in the absence of ligand.
Many receptor tyrosine kinases are 
activated when two receptor monomers 
are brought together and thus are subjected 
to transphosphorylation. However, in 
some biochemical and structural studies 
with dimerising receptors, it has been 
found that only part of the dimers have 
such conformations, that they can 
participate in trans-autophosphorylation 
and stimulation of downstream signalling 
proteins (Lemmon and Schlessinger, 
1994). Dimerisation is thus not always 
suffi cient for the activation. It is thought 
that receptor monomers are in equilibrium 
with receptor dimers and that active dimers 
exist even in the absence of ligand. Ligand 
binding to the extracellular domain of the 
receptor stabilises the formation of active 
dimers and consequently stimulation 
of downstream signalling molecules 
(Schlessinger 2000). This model has 
also been proposed for RET, with the 
addition of GFRα (Bespalov and Saarma, 
2007). In this model, the equilibrium 
is formed between monomers of RET 
and GFRα, inactive and active forms of 
RET dimers and inactive GFRα2-RET2 
heterotetramers. In addition to ligand 
binding, the equilibrium can be pushed 
towards the active dimers by increasing 
the receptor density on the cell surface. 
This model is supported by the finding 
that ligand-independent activation of RET 
occurs when RET is over-expressed, as is 
demonstrated in this study (III).
3.1    The structure of GFLs
GFLs belong to the cystine knot growth 
factor family based on their amino acid 
sequence and spatial structures (Lin et al., 
1993, Eigenbrot and Gerber, 1997, Silvian 
et al., 2006). The members of this family 
contain seven cysteine residues with the 
same relative spacing. The structures 
of GDNF and ARTN have been solved 
(Eigenbrot and Gerber, 1997, Silvian et 
al., 2006), but both lack the structure of 
the flexible N-terminus. In GDNF, this 
N-terminus is prominent and covers about 
1/4 of the total sequence. The analysis 
of these structures has demonstrated 
that, in spite of the low amino-acid 
sequence homology, GFLs resemble 
structurally members of the TGF-β 
superfamily. Moreover, the head-to-tail 
dimerisation, supported by an interchain 
disulphide bond, is similar to other TGF-β 
superfamily members.
The structure of both GDNF (Figure 
5) and ARTN contain the same basic 
elements. The monomer consists of a 
central well-ordered α-helix, the “wrist” 
or “heel” of the monomer, which is 
surrounded by flexible, less-ordered 
stretches. From these stretches start the 
two “fi ngers”, regions formed mainly of 
β-sheets. The N-terminal fi nger 1 contains 
two uninterrupted anti-parallel β-sheets, 
separated by a turn of 310-helix; the 
C-terminal fi nger 2 contains four β-sheets, 
interrupted by short stretches. The dimer 
arrangement is anti-parallel, which creates 
symmetry and suggests symmetric binding 
sites for a dimerised receptor (Eigenbrot 
and Gerber, 1997, Silvian et al., 2006). 
This is confi rmed by the GDNF2-GFRα12 
complex structure (IV).
However, there are some differences: 
the shape and possibly the fl exibility of 
the elongated homodimer differs. Unlike 
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GDNF, ordered segments in the pre-helix 
and post-helix stretches of ARTN increase 
the hinge angle between the “fi ngers” and 
“wrist” of each monomer (Silvian et al., 
2006). In addition, the pre-helix stretch 
of ARTN contains a positively charged 
heparin consensus sequence XBBXBX, 
where B is a basic residue and X is any 
residue. This region has been shown to 
contain the key heparin-binding residues 
in ARTN (Silvian et al., 2006). The same 
region in GDNF is negatively charged, but, 
in the post-helix region, there is a putative 
heparin-binding sequence SRSRRL (Lin et 
al., 1993, Silvian et al., 2006). Moreover, 
Alfano et al. (2007) have localised a 
heparin-binding region in the N-terminal 
part of GDNF (see Figure 1).
Mutagenesis has been performed on 
GDNF to determine its interfaces with RET 
and GFRα1 (Eketjäll et al., 1999, Baloh 
et al., 2000). Eketjäll et al. found four 
negatively charged (D52, E61, E62 and 
D116) and four hydrophobic residues (I64, 
L114, Y120 and I122) in GDNF which 
seem to be crucial for GFRα1 binding. In 
addition, they found some residues (such 
as E58, K60 and L118) where mutations 
caused smaller effects, and which may 
also participate in forming the interface. 
Baloh et al. (2000) identifi ed two critical 
regions in GDNF for the interaction with 
GFRα1 and one region critical for the 
alternate GDNF-GFRα2 interaction. The 
identified regions are not continuous in 
the primary sequence of GDNF, but, in the 
crystal structure, they are directly adjacent 
and located in the fi nger 2. Moreover, they 
identifi ed an additional region in the heel 
region that is critical for the NRTN-GFRα2 
and ARTN-GFRα3 interactions. 
3.2    The structure of GFRαs
The fi rst secondary structure predictions 
suggested that GFRαs are mainly α-helical 
and consist of three conserved cysteine-
rich domains that are joined together 
by less conserved adapter sequences 
(Airaksinen et al., 1999). Later Scott 
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Figure 5. The structure of a GDNF homodimer.  The crystal structure of each GDNF monomer 
(light blue and pink) contains residues 34-134. Fingers 1 and 2 and the N-terminal end of the 
structure (N) are marked in the fi gure. The tips of the fi ngers are predicted to be important in 
binding to GFRα1. The cystine knot (disulphide bridges shown in purple and yellow) is located 
in the centre of the homodimer. Figure kindly provided by Vimal Parkash.
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and Ibáñez (2001) proposed that the 
region containing domains 2 and 3 forms 
only one domain. They also mapped the 
ligand binding sites in GFRα receptors by 
analysing the ligand binding and signalling 
capacities of a variety of chimeric and 
truncated receptors. The major determinant 
of ligand binding was found in the central 
region of the GFRα receptors, which is 
the most conserved region. The authors 
suggested this region to comprise of four 
α-helices and two β-strands.
Two motifs, the hydrophobic triplet 
MLF in the fi rst predicted β-strand and the 
basic triplet RRR, were found to mediate 
the binding to GDNF, but not to RET. The 
N-terminal domain (domain 1) was found 
to be dispensable for both specifi c ligand 
binding and RET phosphorylation, and the 
authors speculated that it could possibly 
have a function in subcellular sorting or in 
the interaction with other transmembrane 
molecules (Scott and Ibáñez, 2001). In 
another study (Wang et al., 2004), residues 
N152, N153, R259, S316, N317 and 
S318 in the GFRα1 central region were 
found to be critical for GFRα1 binding to 
GDNF and eliciting downstream signal 
transduction.
The fi rst crystal structure of the domain 
3 (D3) of GFRα1 receptor revealed a 
novel protein fold (Leppänen et al., 2004). 
D3 forms a bundle of fi ve α-helices with 
fi ve disulphide bridges. Three helices (α1, 
α2 and α4) form a central spiral and the 
core of the bundle contains hydrophobic 
residues from these helices. The three 
most buried phenylalanines (F263, F328 
and F332) are highly conserved among 
mouse GFRα sequences (Lindahl et al., 
2000). Three hydrophobic patches that 
might be involved in interactions with 
other domains, GDNF, RET or other 
proteins were identifi ed in D3.
The structure of GFRα1 domain 3 was 
also used to model the homologous domain 
2 (D2) (Leppänen et al., 2004). This model 
suggested that D2 and D3 are clearly 
separate and D2 consists of fi ve α-helices, 
but has a more compact structure than D3 
(Figure 1). The surface of D2 was found 
to have two large positively charged areas. 
One of them is defi ned by R224, R225, 
R217, H207 and K150, and the second 
positively charged area is characterised 
by a potential heparin-binding motif 
BBBXBBXXB (residues 189–197).
A model of the GDNF-GFRα1 
interface was built using the D3 crystal 
structure, D2 model, and previous 
information about the interacting regions 
in GDNF and GFRα1 (Eketjäll et al., 1999, 
Scott and Ibáñez, 2001). This model served 
as a basis for a site-directed mutagenesis 
strategy and subsequent biochemical 
characterisation of the mutants. Four 
mutants with impaired GDNF-binding or 
effects on RET phosphorylation (F213A, 
R224A, R225A and I229A) were found 
(Leppänen et al., 2004). These residues 
were thus suggested to be located in the 
GFRα1-GDNF interface. In addition, one 
mutant (R217E) showed similar binding 
in the presence and absence of RET, 
which indicates that it may be involved 
in the allosteric properties of GFRα1 or 
in binding RET. This data confi rmed that 
the triplet RRR suggested by Scott and 
Ibáñez (2001) is indeed important, but of 
the hydrophobic MLF triplet, only F213 
interacts with GDNF. However, the results 
of this study (Leppänen et al., 2004) do 
not support the fi ndings of Wang et al., 
(2004).
Recently, the structure of ARTN 
complexed with its receptor GFRα3 
was published (Wang et al., 2006). The 
structural study was complemented with 
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biochemical assays. It was shown that 
D2 and D3 are separate, but together 
form a compact globular structure. Each 
domain consists of fi ve α helices (α1–α5 
for D2, α6–α10 for D3) that form one 
roughly triangular spiral in each domain. 
The interface between the two domains 
forms a large hydrophobic core where 
the residues involved in the hydrophobic 
interactions include L200, F204, L216, 
L217, L289, Y292, L293, I296, F304 and 
I345, which are highly conserved in all 
GFRα receptors. The disulphide pattern of 
D2 is similar to that of D3.
D3 does not form any contacts to the 
ligand, in contrast to the speculations in 
Leppänen et al. (2004). The interaction 
between ARTN and GFRα3 occurs so 
that the finger tips of ARTN insert into 
the pocket created by the triangular spiral 
of α-helices. 16 residues from ARTN 
and 19 residues from GFRα3 form the 
interface, which buries a total surface area 
of about 1500 Å2. ARTN-GFRα3 contact 
interface contains both apolar and polar 
residues that are conserved in GFLs and 
GFRα receptors (Wang et al., 2006). The 
authors suggest that these residues serve 
as the common anchor points in all GFL-
GFRα pairs, which are then surrounded 
by specifi city determinants unique to each 
GFL-GFRα pair.
Based on previous studies of the RET-
binding interface of GFRαs and conserved 
residues that are exposed on the surface 
of GFRαs, the authors propose that a 
surface of GFRα3 including residues from 
helices α2, α3, α7, α8, α9 and α10 (both 
from D2 and D3) forms part of the RET-
binding surface. This RET-binding surface 
would be located adjacent to the two 
fi ngers in ARTN, which could form part 
of the composite RET interaction surface. 
However, these predictions have not been 
confi rmed experimentally.
3.3    The structure of RET
In spite of several attempts, the complete 
crystal structure of RET has not been 
solved yet. However, the intracellular 
TK domain structure of both the non-
phosphorylated and phosphorylated 
forms is available (Knowles et al., 2006). 
According to a molecular modelling, 
mature RET comprises four cadherin-
like domains (residues 29-516), a 
cysteine-rich domain (residues 517-635), 
a transmembrane domain (residues 636-
657), a juxtamembrane domain (residues 
658-723), a kinase domain (residues 724-
1016), and a C-terminal tail (Anders et al., 
2001, Runeberg-Roos and Saarma, 2007) 
(see Figures 2 and 7B).
The domain structure of RET 
resembles that of other RTKs, but the 
extracellular domain is exceptional in that 
it consists of four cadherin-like domains 
(CLDs) (Anders et al., 2001). Cadherins 
need calcium for their function: bound 
calcium ions linearise and rigidify the 
molecule, promote dimerisation and 
protect the cadherin from proteolytic 
degradation (Nagar et al . ,  1996). 
Binding of calcium to RET between each 
cadherin-like domain may also induce 
linearisation and rigidification of the 
whole extracellular region of RET, and 
promote its dimerisation (Anders et al., 
2001). Calcium has indeed been shown 
to be important for the correct folding 
of RET (van Weering et al., 1998) and 
its ligand-induced activation (Nozaki 
et al., 1998). It has been suggested that 
the three first N-terminal cadherin-
like domains of human RET contain an 
extended ligand binding surface and that 
the GFRα1 binding interface is located in 
the fi rst N-terminal cadherin-like domain 
(Kjaer and Ibáñez, 2003). However, in 
another study, it was found that CLD4 and 
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cysteine-rich domain (CRD) are required 
for binding of RET to GFRα1/GDNF, and 
RET did not get cross-linked to GDNF in 
the absence of GFRα1 (Amoresano et al., 
2005).
The cysteine-rich domain located next 
to the four cadherin-like domains consists 
of 117 amino acids of which 16 are 
cysteines. Of the total 28 cysteine residues 
that are present in the extracellular domain 
of RET, 27 are conserved in the human 
and mouse RET proteins (Takahashi et 
al., 1989), suggesting that most of these 
cysteine residues could be involved in the 
formation of intrachain disulfide bonds 
that contribute to the formation of the 
tertiary structure of the RET protein (Asai 
et al., 1995). In addition, the cysteine-rich 
domain has been suggested to participate 
in GFRα binding (Amoresano et al., 
2005).
The transmembrane domain of RET 
has been suggested to be involved in 
non-covalent interactions between two 
RET molecules, which may contribute 
to keeping receptor molecules in the 
proximity of each other and allow RET 
homodimers to be formed (Kjaer et al., 
2006). The intracellular juxtamembrane 
domain is located right between the cell 
membrane and the kinase domain. Thus it 
has not been expected to participate in RET 
signalling directly. However, one Tyr687 
in this part of RET has been shown to get 
phosphorylated in vitro (Liu et al., 1996) 
and both this tyrosine and Ser696, which 
functions as a protein kinase A binding 
site, are involved in the modulation of 
RET kinase activity by cyclic adenosine-
3’,5’-monophosphate (cAMP) (Fukuda 
et al., 2002). By studying S697A knock-
in mice it has been found that Ser697 
(Ser696 in human RET) is required for 
the migration of enteric neural crest cells 
in mouse developing gut and a S697A 
mutation leads to the absence of enteric 
nervous system in the distal colon (Asai et 
al., 2006).
Most of the intracellular part consists 
of the kinase domain, the structure of 
which has been recently solved (Knowles 
et al., 2006) (see also Figure 2). The RET 
kinase domain adopts a characteristic 
protein kinase fold consisting of a smaller 
N-lobe (residues 713-805) and a larger 
C-lobe (residues 812-1013), connected by 
a linker (residues 806-811). This domain is 
followed by a C-terminal tail, the length 
of which differs in different RET splice 
variants.
4. RET-dependent GFL-signalling
All GFLs signal through the receptor 
tyrosine kinase RET, which is activated 
only if the GFL binds a GFRα receptor. 
GDNF binds preferably to GFRα1, 
NRTN to GFRα2, ARTN to GFRα3 and 
PSPN to GFRα4. However, some cross-
talk between the ligands and receptors 
can occur, although its significance in 
vivo is not clear (Airaksinen and Saarma 
2002). Binding of GFL and GFRα to 
RET leads to phosphorylation of the 
intracellular tyrosine kinase domain of 
RET. Phosphorylated tyrosine residues 
then function as docking sites for various 
adapter proteins mentioned below, which 
in turn activate further signalling proteins 
belonging to cellular signalling cascades 
that regulate cell survival, differentiation, 
proliferation, migration, chemotaxis, 
branching morphogenesis,  neurite 
outgrowth and synaptic plasticity.
4.1 Activity of the RET kinase 
domain
RET has 18 intracellular tyrosine residues 
that form putative phosphorylation sites. In 
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a study, in which in vitro phosphorylation of 
RET was followed by mass spectrometric 
analysis, it was found that tyrosines 
806, 809, 900, 905, 981, 1062, 1090 and 
1096 (in human RET) are putative RET 
autophosphorylation sites (Kawamoto et 
al., 2004). In addition, Liu et al. (1996) 
have indentifi ed four additional in vitro 
tyrosine phosphorylation sites: Tyr687, 
Tyr826, Tyr1015 and Tyr1029. However, 
only fi ve tyrosines that are located in the 
kinase domain and C-terminal tail of RET 
(Tyr905, Tyr981, Tyr1015, Tyr1062 and 
Tyr1096) have – with the aid of specifi c 
antibodies – been shown to be activated by 
ligand-stimulation (Salvatore et al., 2000, 
Tsui-Pierchala et al., 2002a, Coulpier et 
al., 2002, Encinas et al., 2004).
Traditionally, the activity of the 
kinase domain of RET is believed to 
depend on a transphosphorylation reaction 
between two adjacent RET molecules. The 
majority of the previously characterised 
non-phosphorylated RTK forms have low 
catalytic activity because of a suboptimal 
conformation of a so called activation 
(A)-loop that interferes with either the 
ATP- or substrate-binding structures of 
RTKs (reviewed in Schlessinger, 2003). 
Phosphorylation of the A-loop causes 
structural changes that relieve this 
autoinhibition of kinase activity.
Comparison of the crystal structure 
of the kinase domain of phosphorylated 
and non-phosphorylated RET reveals 
that the three-dimensional structure 
of the kinase domain of RET does not 
depend significantly on the A-loop 
phosphorylation state (Knowles et al., 
2006). Moreover, enzyme kinetic data 
show that the tyrosine phosphorylated 
form of RET is only slightly more active 
than the non-phosphorylated form. The 
authors thus suggest that there could be 
some other inhibitory mechanism for the 
autoregulation of RET kinase activity 
(Knowles et al., 2006). However, in this 
study, RET was only phosphorylated 
on tyrosine residues, so the regulation 
may happen through serine/threonine 
phosphorylation.
4.2 Downstream signalling
Several signalling pathways are activated 
by GFL-stimulated RET (Figure 6). 
Of the phosphorylated tyrosines that 
form docking sites for adaptor proteins, 
phosphorylated Y1062 is a binding site 
for the largest variety of adaptor proteins. 
Phosphorylated Y1062 binds SHC (Asai 
et al., 1996, Arighi et al., 1997), FGF 
receptor substrate 2 (FRS2) (Kurokawa 
et al., 2001), insulin receptor substrate 1 
(IRS1) (Melillo et al., 2001), Dok1/4/5/6 
(Murakami et al., 2002, Grimm et al., 
2001, Crowder et al., 2004), Enigma 
(Durick et al., 1998) and protein kinase 
C α (PKCα) (Andreozzi et al., 2003). 
Y1062 has been shown to be important 
for the transforming ability of mutant RET 
(Asai et al., 1996) and for self-renewal of 
spermatogonial stem cells and regulation 
of their differentiation (Jijiwa et al., 
2008). 
Of other phosphotyrosines that 
function as docking sites for adaptor 
proteins, phosphorylated Y905 is a 
binding site for GRB 7/10 (Pandey et al., 
1995, Pandey et al., 1996), phosphorylated 
Y981 for Src (Encinas et al., 2004), 
phosphorylated Y1015 for phospholipase 
Cγ (PLCγ) (Borrello et al., 1996) and 
phosphorylated Y1096 for GRB2 
(Alberti et al., 1998). Moreover, it has 
been shown that the oncogenic multiple 
endocrine neoplasia (MEN) 2A form 
of RET activates signal transducer and 
activator of transcription 3 (STAT3) via 
Y752 and Y928 (Schuringa et al., 2001). 
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In addition to phosphorylated tyrosines, 
the elevation of cAMP levels causes 
Ser696 phosphorylation. This serine 
phosphorylation promotes lamellipodia 
formation of neuronal cells (Fukuda et 
al., 2002), regulates the c-Jun N-terminal 
kinase (JNK) signalling pathway and 
controls the migration of enteric neural 
crest cells in the developing gut (Asai et 
al., 2006).
Upon ligand stimulation, at least 
two distinct protein complexes assemble 
on phosphorylated Y1062 via SHC. 
The recruitment of GRB2/Sos (son of 
sevenless) leads to activation of the 
RAS/ERK (rat sarcoma oncogene/
extracellular signal-regulated kinase) 
pathway, while the recruitment of GRB2/
GAB1 (GRB2 associated binding protein 
1) leads to the activation of the PI3K 
(phosphatidylinositol-3-kinase)/AKT 
pathway, which has been shown to be 
involved in the formation of lamellipodia 
(van Weering et al., 1997) and cell 
survival (Maeda et al., 2004). The GRB2/
GAB1 complex can also assemble directly 
onto phosphorylated Tyr1096, offering 
an alternative route to PI3K activation by 
GDNF (Besset et al., 2000, Hayashi et 
al., 2000). Moreover, the JNK pathway 
is activated mainly through tyrosine 1062 
(Chiariello et al., 1998, Hayashi et al., 
2000).
The downstream signalling capacity 
of RET has been shown to be negatively 
regulated by Sprouty2 protein, which 
is a common regulator of downstream 
signalling initiated by RTKs (Chi et al., 
2004, Ishida et al., 2007). In addition, 
RET interacts with protein phosphatases 
LAR (leukocyte common antigen-related 
protein, Qiao et al., 2001), Shp-1 and Shp-2 
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Figure 6.  Signalling pathways mediated by RET. Five tyrosines in the kinase domain of 
RET (purple) have been shown to get phosphorylated by ligand stimulation. In addition, the 
oncogenic MEN 2A form of RET activates STAT3 via Y752 and Y928. Phosphorylated Y1062 
forms as a docking site for a large variety of proteins. It has been shown to bind SHC, FRS2, 
IRS1, Dok1/4/5/6, Enigma and PKCα, which activate RAS/ERK, GRB2/GAB1, JNK and PI3K/
AKT pathways. Phosphorylated Y905 is a binding site for GRB7/10, phosphorylated Y981 for Src, 
phosphorylated Y1015 for PLCγ, and phosphorylated Y1096 for GRB2. Modifi ed from Kodama 
et al., 2005.
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(SH2-containing tyrosine phosphatase 
1 and 2, Incoronato et al., 2004), and 
PTPRJ (receptor-type protein tyrosine 
phosphatase J, Iervolino et al., 2006). 
Both LAR and PTPRJ seem to reduce the 
constitutive tyrosine autophosphorylation 
and kinase activity of RETMEN 2A, but not 
RETMEN 2B (Qiao et al., 2001, Iervolino et 
al., 2006).
Although many signalling pathways 
activated by RET have been identified, 
until quite recently, most of the information 
of the genes that are targeted by the 
signalling molecules activated by RET has 
concerned the oncogenic function of RET 
(Califano et al., 1995, Carlomagno et al., 
1996, Watanabe et al., 2002, Jain et al., 
2004). However, more information about 
the modulation of gene expression by 
normal GDNF/RET signalling is emerging. 
It is now known that GDNF elevates the 
expression of the tyrosine hydroxylase 
gene at both mRNA and protein levels in 
cells expressing RET (Xiao et al., 2002). 
The expression of a zinc finger protein 
GZF1 (GDNF-inducible zinc fi nger gene 
1) has been found to be induced during 
GDNF/RET signalling and it plays a role 
in renal branching morphogenesis (Fukuda 
et al., 2003, Morinaga et al., 2005). Very 
recently, it was reported that expression 
of the transcriptional repressor BMZF3 
(bone marrow zinc finger 3) is also 
induced by GDNF (Suzuki et al., 2008). 
The signalling pathways leading to these 
transcriptional modulations are, however, 
still unknown. 
4.3  Signalling by different ligands
All members of the GDNF ligand family 
utilise RET as a signalling receptor and 
specificity is achieved by their binding 
to different GFRα molecules. It could be 
expected that they could activate RET 
in different ways, for example through 
differential tyrosine phosphorylation, 
or differences in strength and duration 
of phosphorylation. However, it is still 
unclear whether GFLs differ in their 
signalling via RET.
Phosphorylation and dephosphory-
lation of the key tyrosine residues in 
RET (Y905, Y1015, Y1062 and Y1096) 
after stimulation with GFLs that utilise 
different GFRα receptors has been studied 
thoroughly, but no signifi cant differences 
were found (Coulpier et al., 2002). This 
observation suggests that the RET receptor 
is unable to discriminate among different 
ligands or GFRα co-receptors. In a later 
study, differences in the phosphorylation 
profi le as well as cellular responses were 
found after GDNF and NRTN stimulation 
of cells that express only GFRα1 (Lee et 
al., 2006), but further studies are needed 
to confi rm these preliminary results. Even 
if no differences in RET signalling could 
be confi rmed, possible differences in the 
biological activities of different GFLs 
could still be explained by the differential 
tissue-specific and developmentally 
regulated expression pattern of GFLs, 
and the existence of RET-independent 
signalling mechanisms.
4.4 Subcellular localisation of RET
In many cell types, RET is expressed as 
two forms – a 150 kDa form and a 170 kDa 
form – which differ in their subcellular 
localisation. Both forms of RET are 
produced from a single polypeptide of 120 
kDa by posttranslational glycosylation 
(Takahashi et al., 1991). Both 150 kDa 
and 170 kDa forms have tyrosine kinase 
activity (Takahashi et al., 1993). The 
150 kDa isoform is endoglycosidase 
H-sensitive, showing that it is an 
incompletely processed form of RET, 
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present in the endoplasmic reticulum 
(Asai et al., 1995). Cell fractionation 
experiments have shown that the 170 kDa 
isoform of RET is present at the plasma 
membrane, indicating that the 170 kDa 
protein represents the mature glycosylated 
form of RET (Takahashi et al., 1993). 
It has been shown that single point 
mutations in the calcium-binding cadherin-
like domains of RET, or calcium depletion, 
completely abolish cell surface expression 
of the mature form of RET (Asai et al., 
1995, van Weering et al., 1998). Both 
seem to lead to improper processing of 
RET in the ER. Decreased expression 
of mature RET during embryonic 
development underlie the defects observed 
in Hirschsprung’s disease (HSCR) patients 
(Schuchardt et al., 1995). Many mutations 
in the extracellular part of RET also 
decrease significantly the transforming 
activity of RET with MEN 2A mutations 
(Carlomagno et al., 1996, Iwashita et al., 
1996).
Like other RTKs, RET can be 
downregulated after ligand-induced 
activation through targeted degradation 
of the receptor itself. However, whereas 
many other RTKs are degraded in the 
lysosome, degradation of RET happens 
predominantly by a proteasome-dependent 
way, which includes polyubiquitination of 
the receptor (Scott et al., 2005, Pierchala 
et al., 2006). Two molecules, Cbl-3 
and CD2-associated protein (CD2AP) 
that are critical regulators of this RET 
downregulation have been found (Tsui 
and Pierchala, 2008). In some conditions, 
ubiquitinated RET has been found to 
colocalise with an early endosome and 
clathrin-coated vesicle marker after 
internalisation (Richardson et al, 2006). 
In addition to RET downregulation, RET 
internalisation is required for the complete 
activation of ERK1/2, but not for the 
activation of AKT (Richardson et al., 
2006). Consistent with this, it has been 
shown that normal endocytic traffi cking of 
epidermal growth factor receptor (EGFR) 
is important for the full activation of ERK1 
and 2 (Vieira et al., 1996).
Like the level of RET, also GFRα1 
and GFRα2 levels on the cell surface 
decline fast after ligand stimulation. This 
suggests that either RET is internalised in 
a complex with GFRα or that GFRαs are 
released from the cell surface by cleavage 
of their GPI-anchor (Pierchala et al., 
2006).
4.4.1 GFL signalling and lipid rafts
Lipid rafts are considered to be special 
cell membrane domains that are enriched 
in sphingolipids and cholesterol. They 
are believed to function as platforms for 
specific proteins (Simons and Ikonen 
1997). It has been suggested that lipid 
rafts could have important functions in 
signal transduction, membrane traffi cking, 
cell adhesion and migration, synaptic 
transmission and cytoskeletal organisation 
(Brown and London 1998, Simons and 
Toomre 2000, Harris and Siu 2002, Tsui-
Pierchala et al., 2002c). GPI-anchored 
proteins have been shown to be sorted to 
lipid rafts and it has been suggested that 
they cluster on the rafts (Brown and Rose, 
1992, Sharma et al., 2004). Many GPI-
anchored proteins are co-receptors for 
transmembrane growth factor receptors 
and it has been proposed that they could 
bring the transmembrane protein into 
contact with raft-associated cytosolic 
signalling molecules like Src family 
kinases (Brown 1993, Simons and Toomre 
2000). However, the detailed properties 
of lipid rafts are still unclear and even the 
existence of lipid rafts has been questioned 
(see Munro, 2003, for a review).
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Lipid rafts have been proposed to be 
involved in GFL signalling in several ways. 
First, Poteryaev et al. (1999) reported that 
GDNF activates Src family kinases RET-
independently through a GFRα1-mediated 
pathway and suggested that this would 
happen in lipid rafts where GFRα1 and 
Src cluster. Later, Tansey et al. (2000) 
found that GPI-anchored GFRα1 recruits 
RET to lipid rafts after GDNF stimulation. 
To determine the functional relevance of 
RET localisation to lipid rafts, the authors 
used an artificial transmembrane (TM) 
form of GFRα1 which is not localised on 
lipid rafts. GFRα1-TM could not recruit 
RET to lipid rafts and led to a signifi cantly 
attenuated activation of AKT and mitogen-
activated protein (MAP) kinases compared 
to cells expressing wild-type GFRα1. This 
led to a decrease in the ability of GDNF to 
cause differentiation and neuronal survival. 
However, as discussed later (I, II), there 
are some severe technical problems in the 
experiments with GFRα1-TM, and the 
conclusions have partly been contradicted 
later by Paratcha et al. (2001).
As mentioned earlier, GFRαs can bind 
ligand and activate RET when provided 
exogenously in soluble form. Therefore, 
it has been suggested that GFRαs could 
capture and concentrate diffusible GDNF 
family ligands from the extracellular 
space, and then present these factors from 
the surface of one cell to afferent RET-
expressing cells (Trupp et al., 1997). 
It has been shown that soluble GFRα1 
mediates recruitment of RET to lipid rafts 
via a mechanism that requires the kinase 
domain activity of RET itself (Paratcha et 
al., 2001). In the same study, it was also 
shown that activated RET associates with 
different adaptor proteins in membrane 
parts with different degree of ordering.
In addition, it has been shown that 
RET localisation to lipid rafts enhances its 
association with Src and that Src activity 
is necessary to elicit optimal GDNF-
mediated signalling, neurite outgrowth, 
and survival (Tansey et al., 2000, Encinas 
et al., 2001). Therefore, it has been 
thought that recruitment of RET to lipid 
rafts may be a critical determinant of RET 
signalling effi ciency. RET in lipid rafts is 
not degraded by the proteasome, and thus 
lipid rafts appear to cluster and protect 
RET from degradation. The authors of this 
study therefore suggest that one function 
of lipid rafts may be to sequester active 
receptors from downregulation (Pierchala 
et al., 2006).
4.5 Cross-talk with other pathways
It has been found that receptor tyrosine 
kinases like EGFR and Trk-type tyrosine 
kinases can be activated by different 
stimuli even in the absence of their 
ligands (Carpenter et al., 1999, Lee and 
Chao 2001). One of these activation 
mechanisms depends on G protein-
coupled receptor (GPCR) activation. This 
kind of cross-talk with another signalling 
pathway is believed to be common for 
receptor tyrosine kinases. Tsui-Pierchala 
et al. (2002b) postulate three possible 
advantages of cross-talk between RTKs 
in the nervous system. First, they suggest 
that, through cross-talk, a growth factor 
can activate signalling pathways that 
cannot be activated through its own RTK 
and thus expand the biological activity of 
the factor. Second, activation of multiple 
RTKs by a single growth factor may 
amplify the signal, and third, prolong the 
activity of a signalling pathway.
Cross-talk of GDNF-RET signalling 
with other signalling pathways has been 
found on three levels: First, cross-talk can 
occur through direct interactions between 
RET and another signal mediating 
Review of the literature
26
protein. An example of this is the cross-
talk between RET and EGFR. It has been 
shown very recently that EGFR can form 
a complex with RET and contribute to 
RET kinase activation, signalling, and 
growth stimulation (Croyle et al., 2008). 
In addition, RET binds directly at least 
PKCα, and activates PKC α, δ and ζ. PKCα 
activation then inhibits RET kinase activity 
by promoting RET phosphorylation on 
serine/threonine. This modulation forms a 
negative feedback loop that controls RET 
signalling (Andreozzi et al., 2003).
Another mechanism for cross-talk 
is modulation of protein amounts by 
regulation of transcription, or degradation 
of the proteins participating in the cross-
talk. A well-studied cross-talk of this kind 
happens between RET and NGF/TrkA. 
It has been shown that TrkA activation 
by NGF promotes RET phosphorylation 
in a GFL-independent manner in mature 
sympathetic neurons (Tsui-Pierchala 
et al., 2002b). However, NGF-induced 
RET phosphorylation both occurs and 
decreases considerably more slowly than 
GFL-induced RET phosphorylation. The 
cross-talk seems to be unidirectional, 
since GDNF does not promote TrkA 
phosphorylat ion.  The mechanism 
by which the cross-talk happens has 
been found recently: NGF inhibits the 
ubiquitin-dependent degradation of RET 
that clears activated RET from the cell 
surface and thus increases the amount 
of phosphorylated RET (Pierchala et al., 
2007).
RET phosphorylation has been shown 
to be regulated by a cAMP-dependent 
protein kinase A (Fukuda et al., 2002, 
Asai et al., 2006). This observation 
suggests that RET activity could be 
regulated by GPCRs. There is indeed 
evidence that endothelin-3 (ET-3), which 
functions through endothelin receptor 
type B (EDNRB), a G-protein coupled 
receptor, modulates the action of GDNF 
(Hearn et al., 1998). These results were 
obtained by testing the growth, survival, 
migration, or neurogenesis in response to 
GDNF and ET-3 in a culture of precursor 
cells of the enteric nervous system, and 
the mechanism of this cross-talk remains 
unknown. It is possible that this cross-
talk happens on a transcriptional level and 
affects the expression levels of the proteins 
of the RET signalling complex.
The third level of cross-talk occurs 
through modulation of localisation. It has 
been shown that the neurotrophic effect of 
GDNF both in vitro and in vivo requires 
the presence of TGF-β (Krieglstein et al., 
1998). In a later study, it was found that 
TGF-β neither upregulates GFRα1 and 
RET genes, nor participates in the direct 
activation of RET. Instead, it seems to 
recruit GFRα1 molecules to the plasma 
membrane. It was also shown that the 
presence of soluble GFRα1 replaces 
TGF-β, supporting the results (Peterziel et 
al., 2002). 
5.  The GFL/GFRα/RET signalling 
pathway and human diseases
5.1 Gain-of-function mutations in 
RET
RET is expressed in many human tumours 
of neural crest origin (Santoro et al., 
1990). Specific autosomal dominant 
gain-of-function mutations in RET cause 
medullary thyroid carcinoma (MTC), 
a tumour of the neural crest-derived 
parafollicular C cells responsible for 
the production of calcitonin. MTC can 
be found in three hereditary cancer 
syndromes: multiple endocrine neoplasia 
(MEN) type 2A and 2B, and familial 
medullary thyroid carcinoma (FMTC). 
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MTC is also the most common cause of 
death in patients with MEN 2A, MEN 
2B and FMTC (Skinner et al., 2005). The 
disease phenotypes correlate with the 
location of the mutation of RET (Figure 
7B). The most common mutations in MEN 
2A and FMTC are located in the cysteine-
rich domain, but FMTC mutations can 
also be found in the tyrosine kinase 
domain. Mutations in MEN 2B are found 
exclusively in the tyrosine kinase domain 
(Mulligan et al., 1995, Eng et al., 1996). 
Recently, it has also been suggested that 
mutations of GFRα4 contribute to MEN 2 
in the absence of RET mutations or modify 
the RET mutation phenotype (Vanhorne et 
al., 2005).
MEN 2A is the most common of these 
cancer syndromes and it is characterised 
by MTC, phaeochromocytoma (PC), and 
hyperparathyroidism (HPT). About 50 % 
of patients develop phaeochromocytomas, 
while only 15-30 % of patients develop 
HPT or parathyroid adenomas (Howe et 
al., 1993, Hansford and Mulligan, 2000). 
MEN 2A is associated most frequently 
with RET mutations of cysteine 634, but 
also of 609, 611, 618 and 620 (Mulligan 
and Ponder, 1995). These substitutions 
leave one cysteine in the cysteine-rich 
domain of RET without a pair, in which 
case it is not able to form a normal 
intramolecular cysteine bridge. Abnormal 
cysteine bridges are then thought to form 
between two RET proteins, leading to 
dimerisation and constant activation 
(Santoro et al., 1995) (Figure 7A). Since 
folding of proteins takes place in the ER, 
it can be thought that the MEN 2A mutants 
of RET dimerise and are activated already 
during their synthesis in the ER, before 
they reach the cell surface.
Also MEN 2B patients suffer from 
MTC, and about half of them develop 
PC. However, HPT is rare in MEN 2B. 
MEN 2B is further characterised by 
developmental abnormalities including 
marfanoid habitus, thickened corneal 
nerves,  and ganglioneuromatosis 
of the buccal membranes and in the 
gastrointestinal tract. MEN 2B is 
considered to be the most aggressive of the 
MEN 2 subtypes, and its symptoms begin 
on average 10 years earlier than in MEN 
2A (reviewed in Hansford and Mulligan, 
2000). The most frequent RET mutation 
in MEN 2B is a single mutation M918T, 
which is found in more than 90 % of cases 
(Eng et al., 1994, Hofstra et al., 1994). In 
addition, mutations in residue 883 have 
been reported (Smith et al., 1997). Both 
amino acids 883 and 918 are located in 
the kinase domain of RET, within the 
substrate binding pocket of RET, and 
their mutations are believed to result in 
altered substrate specifi city of the kinase 
domain (Songyang et al., 1995, Santoro 
et al., 1995) (Figure 7A). As with MEN 
2A, oncogenic MEN 2B forms of RET 
can be expected to be activated during 
their synthesis already in the ER (see also 
Results and discussion, 3).
The third subtype of MEN 2, FMTC, 
is characterised by MTC in four or more 
family members as its only disease 
phenotype. FMTC is generally considered 
the least aggressive of the three cancer 
syndromes with a later onset than MEN 
2A or 2B (Hansford and Mulligan, 2000). 
The mutations in RET are often the same 
as in MEN 2A: mutations of cysteine 
residues 609, 611, 618, 620 and 634 
are found in more than 80 % of FMTC 
families (Mulligan et al., 1995). However, 
these mutations are all pretty common 
and there is no emphasis on one of the 
residues. The most common mutation of 
MEN 2A, C634R is not found in FMTC. 
In some cases, MEN 2A might be diffi cult 
to distinguish from FMTC, if the family 
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Figure 7. Schematic representation of RET and its oncogenic variants. A) Wild-type RET is 
phosphorylated on the cell surface in the presence of GFLs and GFRα receptors. The kinase 
domains of the dimerised RET molecules phosphorylate each other. The dimeric GFL is shown 
in grey and GFRα receptors in blue. The cadherin-like domains of RET are red, the cysteine-
rich domain is green and the kinase domain purple. The most common multiple endocrine 
neoplasia type 2A (MEN 2A) mutations are located in the cysteine-rich domain of RET. The MEN 
2A variants are activated through the formation of abnormal covalent disulphide bridges (the 
black bar) between the extracellular domains of two RET molecules. The MEN 2B mutations are 
located in the intracellular kinase domain and affect the kinase activity. MEN 2B mutants may 
activate signalling cascades either as monomers or as non-covalently associated dimers. The 
papillary thyroid carcinoma (PTC) variants are cytosolic, and the activation of their tyrosine 
kinase domains is driven by the dimerisation of an N-terminally fused unrelated protein (grey). B) 
The extracellular part of RET consists of four cadherin-like domains (CLD) and a cysteine-rich 
domain (CRD). The transmembrane domain (TMD) connects the extracellular and intracellular 
parts. The intracellular part consists of a juxtamembrane domain (JMD), a tyrosine kinase 
domain (TKD) and a C-terminal tail. The most common mutations linked with HSCR, FMTC, 
MEN 2A and MEN 2B are listed under RET. In addition, the positions of phosphorylated tyrosines 
are shown on the lowest row. Modifi ed from Runeberg-Roos and Saarma, 2007.
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is small, and PC and HPT develop late 
(Hansford and Mulligan, 2000).
Another cancer type caused often 
by mutations in RET is papillary thyroid 
carcinoma (PTC). In the thyroid gland, 
RET is highly expressed in parafollicular 
C-cells but not in follicular cells, where 
it can be activated by chromosomal 
rearrangement. In this rearrangement, the 
kinase domain encoding part of the RET 
gene is fused to a dimerising domain, 
encoding part of different unrelated genes 
(Grieco et al., 1990). The fusion usually 
causes formation of a RET/PTC, in which 
the non-RET part tends to dimerise thereby 
spontaneously forming cytoplasmic dimers 
(Figure 7A). As the tyrosine kinase domain 
of the RET receptor is left intact, the 
RET/PTC oncoprotein can bind adaptor 
molecules and activate signalling cascades 
in the cytoplasm (Knauf et al., 2003). 
RET/PTC is found on average in about 20 
% of adult sporadic papillary carcinomas 
and in general RET/PTC incidence is high 
in tumours from patients with a history of 
radiation exposure (Nikiforov, 2008).
5.2 Loss-of-function mutations in 
RET
During embryogenesis, RET is expressed 
in many cell types derived from the neural 
crest. Among these are the vagal neural 
crest and the myenteric ganglia cells, 
which colonise the entire gut (Pachnis et 
al., 1993). Hirschsprung’s disease (HSCR) 
is a congenital disorder that occurs in 
1/5000 live births. It is characterised by 
the absence of enteric ganglia along a 
variable length of the intestine, which 
leads to intestinal obstruction or chronic 
constipation (see Amiel and Lyonnet, 
2001, for a review). 
About 20 % of HSCR cases are 
familial ones, with considerable genetic 
diversity. Studies of the genetic bases 
of HSCR have identified several genes 
linked to the disease, including RET, 
GDNF, NRTN, ET-3, EDNRB, and the 
transcription factors Sox10 and SMAD-
interacting protein-1 (SIP1) (Luo et al., 
1993, Romeo et al., 1994, Ivanchuk et 
al., 1996, Doray et al., 1998, Parisi and 
Kapur, 2000). Heterozygous germline 
mutations in the RET gene are associated 
with HSCR in up to 50 % of familial 
cases and in 15 % of sporadic cases 
(Hofstra et al., 2000). These mutations 
include deletions, insertions, missense, 
nonsense, and frameshift mutations and 
occur throughout the RET gene (Edery 
et al., 1994, Sancandi et al., 2000). The 
majority of these mutations causes either a 
reduction in the amount of RET or the loss 
of RET function (Iwashita et al., 2001).
Functional consequences of HSCR 
mutations correlate with their position 
in the coding sequence. Mutations in the 
extracellular domain interfere with RET 
maturation and impair its translocation to 
the plasma membrane (Kjaer and Ibáñez, 
2003). Mutations in the kinase domain 
may either reduce the catalytic activity, 
or effect the binding of adaptor molecules 
to activated RET (Iwashita et al., 2001, 
Geneste et al., 1999). Some mutations 
in the extracellular cysteines that cause 
HSCR have also been identifi ed in MEN 
2A and FMTC, and MEN 2A/FMTC 
and HSCR co-segregate in a fraction of 
families (Mulligan et al., 1994). This is 
proposed to result from the dual effect of 
the mutation to RET: due to the mutation 
in an extracellular cysteine, the folding 
of RET may not happen normally. The 
impaired maturation of the mutant RET 
leads to a reduced RET level on the cell 
surface, and this level may not be suffi cient 
for keeping the enteric neurons alive. On 
the other hand, intermolecular disulphide 
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bridge formation and the resulting 
dimerisation of mutant RET molecules 
causes the constitutive activation of RET, 
which can be suffi cient in some tissues to 
cause abnormal proliferation and lead to 
the formation of tumours (Takahashi et al., 
1999).
Some GDNF mutations that con-
tribute to HSCR have been reported 
(Ivanchuk et al., 1996). However, it 
seems that these mutations alone do not 
lead to HSCR, but together with other 
mutations, for example in the RET gene, 
contribute to the pathogenesis of the 
disease (Salomon et al., 1996, Eketjäll and 
Ibáñez, 2002). Also the reported mutation 
in NRTN contributing to HSCR is not 
suffi cient to cause the disease (Doray et 
al., 1998). The study, which evaluated 
the link between different polymorphisms 
in GDNF, NRTN, ARTN and PSPN, and 
susceptibility to HSCR, failed to fi nd any 
disease-contributing mutations in ARTN or 
PSPN (Fernandez et al., 2008). Mutations 
in GFRα receptors do not seem to be 
important contributors to HSCR (Borrego 
et al., 2003), but abnormal expression 
of GFRαs in the enteric nervous system 
of some patients may be involved in the 
pathogenesis of HSCR (Lui et al., 2002).
5.3   Parkinson’s disease
PD is a neurodegenerative disorder 
that is, according to the classical 
view, characterised by the progressive 
degeneration of the nigrostr iatal 
dopaminergic pathway, resulting in the loss 
of dopamine (DA) in the basal ganglia. 
However, new studies postulate that PD 
may progress in six neuropathological 
stages, during which different neuron 
populations are affected (Braak et al., 
2004). Lewy bodies, abnormal aggregates 
of proteins consisting mainly of misfolded 
α-synuclein (Spillantini et al., 1997), begin 
to form at defi ned induction sites and their 
formation advances to certain cell types in 
a known order. α-Synuclein exists in many 
neurons of the human nervous system 
and in order to become involved in PD, 
neurons have to express suffi cient levels of 
normal α-synuclein (Braak et al. 2000).
The first two stages of PD are 
presymptomatic, and during this period, 
inclusion body pathology is confi ned to 
the medulla oblongata/pontine tegmentum 
and olfactory bulb/anterior olfactory 
nucleus. At stages 3-4, during which the 
substantia nigra and other nuclear grays 
of the midbrain and forebrain become 
the focus of pathological changes, most 
individuals probably move from the 
presymptomatic phase to the symptomatic 
phase of the illness (Braak et al., 2003). 
In the fi nal stages 5-6, the process enters 
the mature neocortex, and the patients 
manifest the full range of PD-associated 
clinical symptoms (Braak et al., 2004).
The locomotor symptoms of PD arise 
from selective loss of dopamine neurons 
in the substantia nigra pars compacta. 
These neurons project to the putamen 
and the caudate (the striatum) where they 
release dopamine. A loss of greater than 
50-60 % of these neurons is required 
for the manifestation of the symptoms, 
which include resting tremor, akinesia, 
rigidity and bradykinesia (Sian et al., 
1999). Most symptoms of PD can usually 
be effectively treated with L-dopa, but it 
does not attenuate neuronal degeneration. 
Moreover, PD is progressive and the 
majority of patients show a gradual loss of 
L-dopa effi cacy (Lewitt 2008).
GDNF signalling is important in the 
survival of both dopamine neurons and 
motor neurons in vitro (Lin et al., 1993, 
Henderson et al., 1994). GDNF-, GFRα1- 
and RET-deficient mice do not have 
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significant differences in the substantia 
nigra area compared to wild-type mice 
(Schuchardt et al., 1994, Moore et al., 
1996, Pichel et al., 1996, Sánchez et al. 
1996, Cacalano et al., 1998, Enomoto et 
al., 1998). However, as these knock-out 
mice die at birth, it has been diffi cult to 
investigate whether GDNF signalling 
is required for the postnatal survival 
of dopaminergic neurons. Granholm 
et al. (2000) avoided this problem by 
transplanting fetal neural tissues from 
GDNF -/-, GDNF +/-, and wild-type (WT) 
mice into the brain of adult wild-type 
mice and showed that survival of ventral 
mesencephalic DA neurons is dependent 
on GDNF.
In another study, mice with regionally 
selective RET ablations that allow the 
postnatal survival were used to investigate 
the signifi cance of GDNF-RET signalling 
in adult mice nervous system (Kramer et 
al., 2007). It was found that deficiency 
of RET causes progressive and late loss 
of DA neurons in the substantia nigra 
pars compacta, degeneration of DA 
nerve terminals in striatum and reduced 
levels of evoked dopamine release. Aged 
mice lacking RET showed a phenotype 
similar to presymptomatic PD. Thus the 
results suggest that RET is an important 
signalling receptor for the maintenance of 
adult nigrostriatal DA system.
A study (Kowsky et al., 2007), 
in which mice from Kramer et al. 
(2007) were used, demonstrated that 
RET signalling does not promote the 
survival of dopaminergic neurons in 
the MPTP (1-methyl 4-phenyl 1,2,3,6-
tetrahydropyridine) model of Parkinson’s 
disease, but it facilitates the regeneration 
of dopaminergic axon terminals. Pascual 
et al. (2008) reported that their conditional 
GDNF knock-out mice showed a severe 
catecholaminergic cell death that affected 
the locus coeruleus, the substantia nigra 
and the ventral tegmental area. These 
results are in line with the observation that 
the constitutive activity of RET in knock-
in MEN 2B mice increases the number of 
dopaminergic neurons in the substantia 
nigra pars compacta (Mijatovic et al., 
2007).
On the other hand, the studies of Jain 
et al. (2006) on RET conditional mice 
contradict these results. Their results 
indicate that RET is not required for 
survival of midbrain dopaminergic neurons 
in adult mice and RET defi ciency in these 
neurons does not cause major sensorimotor 
abnormalities. However, the differences in 
the results might be explained by the fact 
that Kramer et al. (2007) followed their 
mice for a signifi cantly longer time than 
Jain et al. (2006).
Genetic variation of RET does not 
seem to cause reduced GDNF-RET 
signalling in PD as Lücking et al. (2008) 
could not find any association between 
RET polymorphisms and PD. The authors 
suggest that GDNF-RET signalling 
could be disturbed on some other level 
than genetic. In conclusion, GDNF-
RET signalling seems to be important in 
aging PD model mice, but the connection 
between GDNF-RET signalling and PD 
in humans has not been confi rmed yet. In 
addition, no association between HSCR 
and PD has been found (Lücking et al., 
2008).
6.  Therapeutic use of GFLs
Since their identifi cation as neurotrophic 
factors, GFLs have been considered as 
potential therapeutic agents for treatment 
of neurological diseases. Because of its 
potential in the treatment of PD, GDNF 
has drawn most attention. However, 
lately also NRTN has been shown to 
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have similar potential. In addition, it has 
been found that ARTN reverses nerve 
injury-induced pain behaviour and has 
therapeutic potential (Gardell et al., 2003, 
Sah et al., 2005). PSPN may have clinical 
applications in the treatment of stroke 
(Tomac et al., 2002).
There have been numerous in vivo 
studies investigating the therapeutic 
potential of GDNF. These studies have 
primarily focused on the rodent partial 
lesion model of PD, where the lesion is 
usually caused with 6-hydroxydopamine 
(6-OHDA) and on mouse and the non-
human primate model, where 1-methyl 
4-phenyl 1,2,3,6-tetrahydropyridine 
(MPTP) is commonly used (Hong et al., 
2008).
Many studies have shown that GDNF 
injections into the striatum before or 
after 6-OHDA-administration protects 
nigral dopaminergic cells that would 
otherwise undergo cell death (Sauer et 
al., 1995, Kearns and Gash, 1995, Shults 
et al., 1996, Rosenblad et al., 1998). The 
neuroprotective effects of GDNF seem 
to result from a reduction in oxidative 
stress (Smith and Cass, 2007). Studies in 
the non-human primate model of PD also 
support the fi ndings of the neuroprotective 
effects of GDNF (Gash et al., 1996, Zhang 
et al., 1997, Oiwa et al., 2006). However, 
it has been shown that there is a need for 
continuous GDNF infusion to maintain 
dopaminotrophic effects (Zhang et al., 
1997). Thus, alternative techniques like 
gene therapy with the use of various viral 
vector systems have been considered and 
investigated. Viral delivery of GDNF 
into the brain has been shown to produce 
benefi cial anatomical and functional effects 
(Lawlor and During, 2004). Moreover, 
lately many pharmacological agents, that 
have proven useful in the symptomatic 
treatment of PD, have been recognised as 
modulators of GDNF expression, as well 
of other neurotrophic factors (reviewed in 
Saavedra et al., 2008).
Clinical trials in patients with PD have 
given confl icting results. Transplantation of 
GDNF-treated fetal ventral mesencephalon 
cells increased the survival of dopaminergic 
cells and improved the condition of the 
patients significantly (Mendez et al., 
2000). In an open-label study by Gill et 
al. (2003), GDNF was administered via 
a catheter into the putamen, and it was 
found that the dopamine uptake of cells in 
the putamen increased and PD symptoms 
improved signifi cantly in all fi ve patients. 
Also Slevin et al. (2005) administered 
GDNF into the putamen and found 
considerable improvement in the patients. 
However, in a study, in which GDNF was 
administered via a catheter into the right 
lateral ventricle of a patient, there was no 
evidence of regeneration of endogenous 
dopaminergic nigrostriatal neurons, and the 
symptoms continued to worsen (Kordower 
et al., 1999). In a randomised, double-
blind study of Nutt et al. (2003), GDNF 
was administered through an implanted 
intracerebroventricular catheter. Also in 
this study, GDNF did not seem to have 
any impact in the symptoms. The authors 
note, however, that the reason for this may 
be that GDNF never reached the target 
tissues (putamen and substantia nigra). 
In addition, the latest randomised double-
blind study (Lang et al., 2006), where 
GDNF was administered into the putamen 
of PD patients, showed no significant 
improvement in symptoms. Moreover, 
several adverse effects including nausea, 
loss of appetite, hallucinations and 
depression have been found in some 
studies (Nutt et al., 2003).
The reason for very conflicting 
results is probably the differences in the 
administration methods used: Salvatore 
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et al. (2006) have tested the infusion 
protocol of the phase 2 clinical trial that 
failed in showing any impact for GDNF 
(Lang et al., 2006), and their results show 
that the catheter used did not distribute 
GDNF effi ciently, and the bioavailability 
of GDNF was limited to a small portion 
of the human putamen. A problem in the 
delivery of both GDNF and NRTN into 
the brain is that their diffusion in the target 
tissue is very limited. This seems to be 
caused by the binding of these ligands 
to heparin in the extracellular matrix, 
and heparin can be used to improve the 
distribution (Hamilton et al., 2001).
In addition to GDNF, NRTN has been 
shown to enhance survival of dopaminergic 
neurons in rodent and monkey models of 
PD (Horger et al., 1998, Rosenblad et al., 
1999, Oiwa et al., 2002, Li et al., 2003). 
Quite recently, Fjord-Larsen et al. (2005) 
also reported about a successful lentiviral 
gene transfer of a modifi ed NRTN, which 
protected nigral dopaminergic neurons in 
rats. A phase I clinical trial by Ceregene 
showed promising results (Peterson and 
Nutt, 2008), but the very recent phase II 
clinical trial of NRTN for PD failed to 
demonstrate an appreciable difference 
between patients treated with an adeno-
associated virus (AAV) vector carrying 
the gene for NRTN versus those in the 
control group (Ceregene Press release 
26.11.2008). 
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Aims of the study
AIMS OF THE STUDY
This study aimed at characterising the biochemical and cell biological function as well 
as the structure of components of the GFL signalling system. It had been found that the 
mammalian GFRα1 and GFRα4 receptors differ in that GFRα4 lacks the N-terminal 
domain 1, which is present in all other GFRα receptors. Before this study, the signifi cance 
of domain 1 was unclear. The biochemical and cell biological properties of mouse 
GFRα4 were not very well characterised, and it was not known how the difference in 
the domain structure of GFRα1 and GFRα4 affects their function. Detailed structural 
information of the interactions of GDNF and GFRα1 was also not available. In addition, 
the activity of RET which functions as the signal mediating component of the complex 
had not been studied during its synthesis in the endoplasmic reticulum.
The specifi c aims of the study were to:
Characterise the biochemical and cell biological features of the mouse GFRα4 
receptor and to compare these characteristics to those of GFRα1.
Study the function and signifi cance of domain 1 in GFRα1.
Set up methods and use them to study the activation of RET precursors in the 
endoplasmic reticulum.
Determine the structure of GFRα1 in the complex with GDNF and to verify 
this structure with biochemical experiments. Particularly, we were interested in 
studying the interactions between GFRα1, RET and GDNF.
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MATERIALS AND METHODS
Methods that I have used myself are 
presented here in detail. Methods that I 
have not used or in which my contribution 
has been minor are listed in Table 1 with a 
reference to the publication in which they 
have been used and described.
RET phosphorylation assays 1. 
(used in I-IV)
With soluble GFRα1 receptors1.1 
RET phosphorylation assays with soluble 
GFRα1 receptors were done in two 
different cell lines. PC6-3 cell line that 
expresses low amount of RET, but does not 
express GFRα1 was used in II. MG87RET 
cell line which is stably transfected with 
RET long isoform, but does not express 
GFRα1 was used in II and IV. Cells were 
starved for 4 h in serum-free DMEM 
at +37 °C and subsequently stimulated 
with 0-1000 ng/ml of the soluble GFRα1 
proteins and 100 ng/ml of GDNF for 60 
min at +37 °C. Cells were lysed in the lysis 
buffer containing TBS, 10 % glycerol, 1 % 
Triton X-100, 1 % Nonidet P-40, 2 mM 
EDTA, 1 mM Na3VO4 and Complete Mini 
EDTA-free (Roche GmbH, Germany). The 
nuclei were removed by centrifugation 
(2500 g) and antibodies to RET (Ret C-20, 
Santa Cruz Biotechnology, USA) were 
added to the post-nuclear lysates. 
In II,  immunocomplexes were 
collected with protein G sepharose 
(Amersham Biosciences, UK) and analysed 
by Western blotting with phosphotyrosine 
antibodies (anti-phosphotyrosine 4G10, 
Upstate Biotechnology Millipore, USA). 
Membranes were restained with antibodies 
to RET to ensure that equal amounts of 
RET were present. In IV, lysates were 
used in pRET ELISA (enzyme-linked 
immunosorbent assay) assays (described 
later). The assays were repeated at least 
three times with similar results.
With GPI-anchored GFRα1 1.2 
receptors
In RET phosphorylation assays with GPI-
anchored GFRα1 receptors, two different 
cell lines were used: MG87RET cells (II) 
and PC6-3 cells (II, III). MG87RET cells 
were transfected with GFRα1 constructs 
and PC6-3 cells were transfected with 
GFRα1 and RET constructs. Transfections 
were done with Lipofectamine 2000 
(Invitrogen, USA).
After transfection, cells were starved 
at least for 4 h in serum-free DMEM at +37 
°C and subsequently stimulated with 100 
ng/ml of GDNF (PeproTech UK) for 60 
min at +37 °C. Cells were lysed with the 
lysis buffer described above. The nuclei 
were removed by centrifugation (2500 g) 
and antibodies to RET (Ret C-20, Santa 
Cruz Biotechnology) were added to the 
post-nuclear lysates. Immunocomplexes 
were collected with protein G sepharose 
(Amersham Biosciences) and analysed 
by Western blotting with phosphotyrosine 
antibodies (anti-phosphotyrosine 4G10, 
Upstate Biotechnology). Membranes were 
restained with antibodies to RET to ensure 
that equal amounts of RET were present. 
The assays were repeated at least three 
times with similar results.
Neurite outgrowth assays 2. 
(I-II)
With soluble GFRα1 receptors2.1 
PC6-3 cells were transferred to RPMI 
medium containing 1 % horse serum 
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and 1 % penicillin/streptomycin (Gibco, 
Invitrogen, USA) on plates coated with 
collagen (Becton Dickinson, USA). 
Soluble GFRα1 receptors (1000 ng/ml) 
and GDNF (100 ng/ml) or NGF (50 ng/ml, 
Promega, USA) were added and neurites 
were counted after 3-4 days from living 
cells under the microscope. Only those 
neurites that were longer than the cell 
soma were counted. 200-300 cells were 
counted per sample and the experiments 
were repeated three times with different 
batches of purifi ed GFRα1 proteins.
With GPI-anchored GFRα1 2.2 
receptors
PC6-3 cells on collagen-coated plates were 
transiently transfected with constructs 
encoding GFRα1, GFRα4 and RET, and 
transferred to RPMI medium containing 
5 % horse serum, 2.5 % fetal calf serum 
and 1 % penicillin/streptomycin. GDNF 
or PSPN (100 ng/ml) were added and 
neurites two times longer than the cell 
soma were counted after 4-5 days as 
described above.
Co-immunoprecipitation of 3. 
SHC/RET and GRB2/RET (III)
PC6-3 cells were transiently transfected 
(6 h) with constructs encoding RET 
and GFRα1. In one assay, cells were 
stimulated for 10 min with GDNF (100 
ng/ml). Cells were lysed with the lysis 
buffer described above. The nuclei were 
removed by centrifugation (2500 g). Each 
sample was divided into two parallel parts 
before the immunoprecipitation. From one 
part, SHC-associated proteins were co-
immunoprecipitated (IP) with antibodies to 
SHC (#610081, Transduction Laboratories, 
USA). The SHC-immunoprecipitated 
samples were analysed by Western 
blotting with antibodies to RET and SHC. 
From the other part of the sample RET 
was precipitated with Ret C-20 antibody 
(Santa Cruz Biotechnology). Samples 
were analysed by Western blotting with 
antibodies to phosphotyrosine (4G10, 
Upstate Biotechnology) and RET. 
GRB2/RET co-immunoprecipitation 
was performed similarly but instead of 
antibodies to SHC, antibodies to GRB2 
(C-7, Santa Cruz Biotechnology) were 
used, and the transfection time was 
increased to 10 h.
In another assay cells were stimulated 
for 10 min with GDNF (100 ng/ml) 
in the presence of Brefeldin A (5 μg/
ml, Epicentre Biotechnologies, USA) 
and the samples were lysed with lysis 
buffer described above. RET was 
immunoprecipitated from the samples and 
the precipitates were analysed by Western 
blotting with antibodies to SHC. The 
membrane was restained with antibodies 
to RET. The assays were repeated at least 
three times with similar results.
AKT phosphorylation assay 4. 
in the presence of Brefeldin 
A (III)
AKT phosphorylation assay was done 
in PC6-3 cells which were transiently 
transfected with RET constructs both in 
the absence and presence of Brefeldin A. 
Cells were transfected with Lipofectamine 
2000 (Invitrogen) or MATra-A reagent 
(IBA GmbH, Göttingen, Germany). For 
MATra-A transfection the transfection 
procedure was modified from the 
manufacturer’s instructions: higher 
concentrations of beads and shorter 
incubation time worked better for PC6-3 
cells. After an 8 h expression, cells were 
lysed and the lysates were divided into two 
parts. One part was used as a total lysate 
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for Western blot analysis of phospho-AKT 
(#9271, Cell Signaling Technology, USA). 
The Western blot membrane was then 
reprobed with antibodies to AKT (#9272, 
Cell Signaling Technology). The other part 
was used to check the levels of total RET 
and phosphorylated RET in the samples. 
RET was immunoprecipitated and the 
precipitate was analysed by Western 
blot analysis with antibodies to RET 
(Ret C-20, Santa Cruz Biotechnology) 
and phosphotyrosine residues (anti-
phospho ty ros ine  4G10 ,  Ups ta t e 
Biotechnology). The assays were repeated 
at least three times with similar results.
AKT, ERK and STAT3 5. 
phosphorylation assays with 
ER-retained RET (III)
PC6-3 cells were transiently transfected 
with RET constructs. Western blot analyses 
were carried out from total lysates. The 
antibodies to ERK (K-23), P-ERK (E-4) 
and STAT3 (C-20) were from Santa Cruz 
Biotechnology. The antibodies to AKT 
and P-STAT3 (#9131) were from Cell 
Signaling Technology. The assays were 
repeated at least three times with similar 
results.
Phospho-RET ELISA assays 6. 
(IV)
The  c lea red  lysa tes  f rom RET 
phosphorylation assays (described above) 
were applied on a 96 well plate (OptiPlate 
96 F HB, Black, Wallac), which had been 
previously coated with 0.5 μg/ml of RET 
C-20 antibody (Santa Cruz Biotechnology) 
and blocked with 2 % BSA in TBS, and 
the plate was incubated in +4 °C for 1 
h. Phosphorylated RET was detected by 
anti-phosphotyrosine (4G10, Upstate 
Biotechnology, 1:1000), anti-mouse 
HRP (DAKO A/S, 1:3000) and enhanced 
chemiluminesence reaction (Femto ELISA 
ECL Kit, Pierce). All washes between 
the incubations were done with the same 
washing buffer (TBS, 1 % Triton X-100). 
The signal was detected by counting on 
MicroBeta luminometer (PerkinElmer). 
The assays were repeated at least three 
times with similar results.
Other methods7. 
Table 1. List of methods used by co-authors in 
articles I-IV.
Method Used and 
explained 
in
Creation of GPI-anchored 
GFRα constructs
I, II
RET phosphorylation assay 
with GPI-anchored GFRα4
I
Generation of stable cell lines 
expressing GFRα4
I
Glycosylation assays I
Membrane association assays I
Neuronal survival assay I
Binding and cross-linking of 
PSPN to mouse GFRα4
I
Expression and purifi cation of 
soluble GFRα1 variants and 
RETED
II
Characterisation of purifi ed 
soluble GFRα1 variants
II
GDNF binding to GPI-an-
chored GFRα1 variants
II
Scintillation proximity assays II
Expression and purifi cation of 
the GDNF2-GFRα12 complex
IV
Site-directed mutagenesis of 
GFRα1
IV
MAP kinase activity assays IV
Crystallography IV
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Functional characteristics 1. 
of the mouse GFRα4-GPI 
receptor (I)
In this work we characterised the mouse 
GFRα4 receptor biochemically and cell-
biologically. Previously, it had been 
shown that in the presence of GDNF, 
GFRα1 recruits RET to lipid rafts, and 
it was suggested that this recruitment is 
essential for GDNF-induced downstream 
signalling, differentiation and neuronal 
survival (Tansey et al., 2000). PSPN had 
been found to promote the survival of 
sympathetic neurons, microinjected with 
GFRα4 and RET (Lindahl et al., 2001), 
but the biochemical and cell biological 
features of mouse GFRα4 had not been 
thoroughly characterised. In addition, 
nothing was known about the capacity of 
GFRα4 to recruit RET to lipid rafts in the 
presence of PSPN. 
Biochemical and functional 1.1 
characterisation of the mouse 
GFRα4 receptor
In our first experiments, we transfected 
FLAG-tagged mouse GFRα4 into 
Neuro 2a cells (ATCC) endogenously 
expressing RET. The GFRα4 receptor was 
expressed in the presence and absence of 
tunicamycin, a chemical which prevents 
the N-glycosylation of proteins, and 
the cell lysates were then analysed by 
Western blotting with FLAG antibodies. 
In the presence of tunicamycin, we found 
one band with a molecular weight of 
approximately 31 kDa, whereas in the 
absence of tunicamycin, two bands with 
molecular weights of about 31 kDa and 
33 kDa were detected (I, Figure 1A). 
The FLAG antibody did not recognise 
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any bands from the lysates from non-
transfected cells. We concluded that the 31 
kDa band represents a non-glycosylated 
precursor of the mature 33 kDa GFRα4 
receptor. The glycosylation site is 
predicted to be N184 (Uniprot), but this 
has not been confi rmed experimentally.
The membrane flotation assay and 
subsequent Western blot analysis of the 
fractions showed that the FLAG-tagged 
mouse GFRα4 receptor is located in the 
top fractions of the gradient (I, Figure 
1B). We therefore concluded that the 
receptor is membrane-bound. In addition, 
the cell surface localisation was confi rmed 
with biotinylation of cell surface proteins 
(I, Figure 1D). PI-PLC treatment of the 
cells detached the 33 kDa form of GFRα4 
from the cell surface, which indicates that 
it is bound to the cell surface with a GPI-
anchor (I, Figure 1C). Cross-linking of 
cell surface proteins to125I-PSPN in cells 
that were transfected with mouse GFRα4 
and expressed endogenously RET, and 
subsequent immunoprecipitation with 
RET antibodies revealed two major bands 
that could be displaced with unlabelled 
PSPN (I, Figure 1E). Based on their sizes, 
these bands could represent PSPN-GFRα4 
and PSPN-GFRα4-RET complexes. We 
concluded that the FLAG-tagged mouse 
GFRα4 is a GPI-anchored, cell surface 
located receptor for PSPN.
Our RET phosphorylation assay in 
mouse GFRα4-transfected Neuro 2a cells, 
stimulated with PSPN, showed a clear 
dose-dependent RET phosphorylation (I, 
Figure 1F). In untransfected cells, PSPN 
did not cause RET phosphorylation. 
Therefore, our results show that PSPN 
activates RET through GFRα4. However, 
GDNF caused a clear RET phosphorylation 
in untransfected Neuro 2a cells (I, Figure 
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1G), which indicates that GFRα1 is present 
in these cells in contrast to what has been 
proposed in previous studies (Tansey et al., 
2000, Scott and Ibáñez, 2001). This result 
was verifi ed by PCR (data not shown).
Recruitment of RET to lipid rafts 1.2 
by the GFRα4 receptor
To determine whether GFRα4 can 
recruit RET to lipid rafts in the presence 
of PSPN, we made cell lysates of cells 
that had been transfected with mouse 
GFRα4 and stimulated with PSPN. Triton 
X-100, which dissolves most of the cell 
membranes, but leaves sphingolipid- and 
GPI-anchored protein-enriched membrane 
parts insoluble in +4 °C (Brown and Rose, 
1992), was added to the post-nuclear 
lysates. The detergent-resistant membrane 
parts can be found in the top fraction in 
a membrane fl otation assay. As a marker 
for the Triton X-100 insoluble fraction, 
we used GFRα1 receptor, and as a marker 
for Triton X-100 soluble fractions, the 
transferrin receptor (Tansey et al., 2000). 
As a positive control for RET recruitment, 
we used GFRα1-transfected cells, which 
were stimulated with GDNF.
Although the control GDNF-GFRα1 
sample showed a clear re-localisation 
of RET to the Triton X-100 insoluble 
fraction, and PSPN stimulation caused 
RET phosphorylation in GFRα4-
transfected cells, we found that only very 
little RET was recruited to the Triton 
X-100 insoluble fraction by GFRα4 (I, 
Figure 2). In addition, GFRα4 seemed to 
be less tightly associated with the Triton 
X-100 insoluble fraction than GFRα1. 
We checked by Western blotting 
with RET antibodies that the levels of 
phosphorylated RET were equal in both 
the GDNF/GFRα1 and PSPN/GFRα4 
samples. We also confirmed that the 
FLAG-tag does not disturb the interaction 
of GFRα4 with RET by repeating the 
experiment with human non-tagged 
GFRα4 (Lindahl et al., 2001). Taken 
together, these results show that the 
localisation of GFRα1 and GFRα4 as well 
as their ability to recruit RET in the Triton 
X-100 insoluble fraction are different. This 
difference may cause distinct signalling of 
GDNF/GFRα1 and PSPN/GFRα4 through 
RET, since the signalling molecules, which 
dock in the active RET, may be different 
in membrane parts with different order of 
lipid organisation. Moreover, there might 
be differences in RET internalisation and 
inactivation.
Our results do not explain what causes 
the difference in the localisation of GFRα1 
and GFRα4, or the difference in their 
abilities to recruit RET to lipid rafts. It can 
be speculated that the difference could be 
caused by different GPI-anchors. The GPI-
anchor has a complex structure that can 
be modified with phosphoethanolamine 
groups and sugars, but definitive 
conclusions that relate GPI-anchor 
structure and function have been diffi cult 
to draw (Paulick and Bertozzi, 2008). 
There is no published data on the GPI-
anchor types of GFRα receptors, so further 
characterisation is needed to fi nd evidence 
of this possibility. Another explanation 
for the difference may be that the protein 
interactions in the PSPN/GFRα4/RET 
complex could be more sensitive to Triton 
X-100 treatment than in the GDNF/
GFRα1/RET complex, possibly because of 
the lack of D1 in GFRα4, since D1 seems 
to stabilise the interaction between GDNF 
and GFRα1 (II). RET could therefore be 
released from the complex and the rafts 
during the lysis. However, this would not 
affect the association of GFRα4 with the 
Triton X-100 insoluble fraction alone. 
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More studies are also needed to examine 
these explanations.
The biological activity of the 1.3 
GFRα4 receptor
Because it had been suggested that RET 
recruitment to lipid rafts is essential for 
GDNF-induced cell differentiation and 
neuronal survival (Tansey et al., 2000), 
we wanted to test whether PSPN/GFRα4 
can mediate these effects. The capacity 
of PSPN/GFRα4 to mediate neuronal 
survival was tested in rat cerebellar 
granule neurons transfected with mouse 
GFRα4. Normally, when switched from a 
culture medium containing high K+ levels 
to one containing a low K+ concentration, 
differentiated granule neurons degenerate 
and die (D’Mello et al., 1993). In these 
conditions, only about 5 % of our mock-
transfected cells survived. PSPN supported 
the survival of the GFRα4-transfected cells 
so that about 50 % of these cells survived 
(I, Figure 4A). This survival supporting 
effect was almost as high as that of GDNF 
and GFRα1.
The capacity of PSPN-GFRα4 to 
mediate neuronal differentiation was tested 
in neurite outgrowth assays in PC6-3 cells. 
These cells express endogenous RET 
at low levels, enabling us to see some 
neurite outgrowth after PSPN stimulation 
of GFRα4-transfected cells and a quite 
high induction of neurite outgrowth after 
GDNF stimulation of GFRα1-transfected 
cells. However, after co-transfection with 
GFRα1/RET or GFRα4/RET, both GDNF 
and PSPN induced a high level of neurite 
outgrowth (I, Figures 4B and 4C).
In the study that suggested that 
recruitment of RET to lipid rafts could be 
a critical determinant of RET signalling 
efficiency (Tansey et al., 2000), the 
authors used an artifi cial transmembrane 
(TM) form of GFRα1 that is not localised 
in lipid rafts, and a soluble GFRα1, to 
determine the function of the localisation 
of RET to the rafts. Both receptors 
mediated GDNF-induced phosphorylation, 
but did not recruit RET to lipid rafts, and 
the survival and differentiation promoting 
effect was decreased in comparison to the 
GPI-anchored receptor. In contrast, our 
results clearly show that although GFRα4 
cannot recruit RET in the lipid rafts as 
effi ciently as GFRα1, PSPN/GFRα4 can 
still contribute to neuronal differentiation 
and survival. However, in Tansey et al. 
(2000) the characterisation of GFRα1-TM 
was done in Neuro 2a cells, which were 
in our study found to express endogenous 
GFRα1. Therefore, it remains unclear if 
the GFRα1-TM construct was functional. 
In addition, Paratcha et al. (2001) have 
shown that soluble GFRα1-GDNF 
complex can actually recruit RET by an 
unknown mechanism to lipid rafts and 
potentiate downstream signalling, neuronal 
survival, and differentiation. This study 
also points out some technical problems in 
the setup of experiments in Tansey et al. 
(2000). For these reasons, more studies are 
required in order to assess the importance 
of RET recruitment to the lipid rafts.
In conclusion, we have found that 
GFRα4 has a signifi cantly weaker capacity 
than GFRα1 to recruit RET to the lipid 
rafts. In spite of that, it can phosphorylate 
RET in the presence of PSPN and 
contribute to neuronal differentiation 
and survival. The localisation of RET 
when it gets activated by PSPN-GFRα4 
remains unclear, but it seems clear that – 
in contrast to what has been previously 
suggested (Tansey et al., 2000) – the 
recruitment of RET to the lipid rafts is not 
always crucial for the biological activity 
of a GFRα receptor. Further studies on 
the interactions between different GFRα 
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receptors and RET may shed light on 
the mechanism and signifi cance of RET 
recruitment to the lipid rafts.
The role of domain 1 in the 2. 
function of GFRα1 (II)
As mentioned earlier, the fi rst cysteine-rich 
domain D1 present in GFRα1-3 receptors 
is not present in GFRα4 (see Review of 
the literature, Figure 1). This raises the 
question of the functional signifi cance of 
this domain. The major ligand binding 
region has been found in the D2 of GFRα 
receptors, and the third domain has been 
suggested to interact with RET (Scott and 
Ibáñez 2001, Leppänen et al., 2004, Wang 
et al., 2006, IV), but no function for D1 
had been shown before this study.
In this study, we used both full-length 
and truncated soluble and GPI-anchored 
GFRα1 molecules to study the functional 
role of D1 in GFRα1. Soluble GFRα1 
variants were named GFRα120, GFRα1114 
and GFRα1145, according to the first 
residue in the N-terminus. These variants 
were expressed in Sf9 insect cells and 
purifi ed by Ni2+-affi nity chromatography. 
The purity of the receptors was analysed 
by Western blotting and the proteins were 
quantifi ed on an SDS-PAGE gel. To further 
characterise the GFRα120 and GFRα1145 
variants, these receptors were subjected to 
reverse-phase chromatography, N-terminal 
sequencing, MS-analysis, and gel fi ltration 
fractionation. The GFRα1 containing 
fractions obtained in the gel filtration 
were identifi ed by assessing their GDNF 
binding capacity by scintillation proximity 
assay (SPA) and by Western blotting.
2.1 Characterisation of soluble and 
GPI-anchored GFRα1 receptors
In reverse-phase chromatography, both 
GFRα120 and GFRα1145 eluted as a single 
peak, and in N-terminal sequencing both 
gave a sequence that matches with the 
known sequence of GFRα1. MALDI-TOF 
(matrix-assisted laser desorption/ionisation 
– time-of-fl ight mass spectrometer) MS-
analysis gave molecular masses, which 
indicated that both proteins are post-
translationally modifi ed. The information 
about the sizes of the modifications is 
consistent with previous identifi cation of 
putative N-glycosylation sites in GFRα1 
(Jing et al., 1996). Also the results 
of the assays in which GPI-anchored 
GFRα1 variants GFRα1WT and GFRα1122 
(named according the first residue in 
the N-terminus) were expressed in the 
presence or absence of tunicamycin, and 
then analysed in Western blotting, showed 
corresponding differences in molecular 
masses (II, Figure 2). Thus, we concluded 
that, as expected, both GPI-anchored 
GFRα1 variants were N-glycosylated and 
the glycosylation seemed to correspond to 
the glycosylation of the soluble GFRα1s. 
Gel fi ltration chromatography, followed 
by Western blotting and the SPAs, showed 
that both soluble GFRα1 variants were 
monomeric (II, Figure 1). This analysis 
also showed that the purified proteins 
could actively bind GDNF.
2.2 Differences in GDNF binding 
and biological activity between 
truncated and full-length GFRα1
The cell-based binding assays of GDNF 
to both full-length and truncated GPI-
anchored GFRα1 variants were carried 
out to study whether the D1 of GFRα1 has 
any impact on ligand binding capacity. An 
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IC50 of 1.12 ± 0.14 nM (mean ± S.E.M.; 
n = 4) was determined for the binding of 
125I-GDNF to GFRα1WT, and an IC50 of 
2.06 ± 0.40 nM for the binding of 125I-
GDNF to the GFRα1122 (II, Figure 3A 
and Table 1). RET has been shown to 
stabilise the binding of GDNF to GFRα1 
(Cik et al., 2000, Leppänen et al., 2004) 
and, to assess whether D1 has any effect 
on this, the binding assays were also done 
in the presence of RET. RET stabilised 
the binding of GDNF to GFRα1WT by a 
factor of 2.3, and the binding of GDNF 
to GFRα1122 by a factor of 2.7 (II, Figure 
3B and Table 1). Thus, D1 seems to be 
important for binding of GDNF, but not 
for the interaction with RET.
These results were confirmed with 
the soluble GFRα1 variants in a cell-
free SPA. The results were consistent 
with the results from the binding assays 
with GPI-anchored GFRα1s: The IC50 of 
the binding of 125I-GDNF to GFRα20 and 
GFRα145 were 0.75 ± 0.15 and 1.59 ± 0.18, 
respectively (II, Figure 3C and Table 2). 
Also the stabilising effect of RET was 
approximately as strong with the full-
length and the truncated GFRα1 receptors 
(II, Figure 3D and Table 2). In addition, 
this cell-free binding assay confirmed 
that D1 stabilises the binding of GDNF, 
without any other components like Met 
receptor, heparin or NCAM that have 
been suggested to interact with GDNF-
GFRα1 (Popsueva et al., 2003, Rickard 
et al., 2003, Paratcha et al., 2003). Taken 
together, the results of the binding assays 
show that the presence of D1 stabilises the 
binding of GDNF to both the soluble and 
GPI-anchored receptor.
The ability of the soluble GFRα1 
variants to mediate GDNF-induced neurite 
outgrowth was studied in neurite outgrowth 
assays in PC6-3 cells. The assays were 
repeated three times with three different 
batches of soluble GFRα1 proteins. In 
these assays full-length GFRα1 was more 
than 2-fold more active than either of the 
truncated receptors (II, Figure 4A). None 
of the receptors induced neurite outgrowth 
without GDNF, as was expected. The 
phosphorylation of endogenous RET 
seen in lysates of these GDNF-GFRα1WT-
induced cells confirmed that neurite 
outgrowth is linked with endogenous RET 
phosphorylation, induced by the soluble 
GFRα1 and GDNF (II, Figure 4B).
2.3    The effect of GFRα1 
concentration on RET 
phosphorylation
Similar assays were also done to determine 
how the truncated GFRα1 variants can 
induce RET phosphorylation. Assays done 
with GPI-anchored GFRα1 receptors in 
MG87RET cells showed that GDNF alone 
does not induce any RET phosphorylation, 
but transfection of GFRα1WT and GFRα1122 
enable equally strong phosphorylation 
(II, Figure 5A). Thus, according to these 
results, D1 would not have any effect on 
RET phosphorylation.
Since the binding assays, as well as 
the neurite outgrowth assays done with 
soluble GFRα1 variants, however, show 
a clear difference between the full-length 
and the truncated receptor, we concluded 
that the high expression levels of GPI-
anchored GFRα1 receptors could mask 
the impaired function of the truncated 
receptors. In this case, we might be able 
to see differences between the full-length 
and truncated GFRα1 variants when 
the number of GFRα1 receptors is the 
limiting factor in the GDNF-GFRα1-RET 
complex formation. We set up to study 
this hypothesis by performing the RET 
phosphorylation assays with increasing 
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concentrations of the soluble GFRα1 
variants.
The results of these assays indeed 
showed that, at low concentrations, 
the full-length GFRα120 together with 
GDNF induced RET phosphorylation 
more effi ciently than any of the truncated 
receptors: GFRα120 induced maximal RET 
phosphorylation already at a concentration 
of 100 ng/ml whereas GFRα1114 and 
GFRα1145 reached the maximal level only 
at concentrations of 500-1000 ng/ml (II, 
Figure 5B).
2.4    Domain 1 stabilises the GFRα1-
GDNF interaction, affects RET 
phosphorylation and contributes 
to the biological activity in vitro
Our results show that RET stabilises 
the binding of GDNF to the truncated 
and full-length forms of GFRα1 equally 
well. Therefore, it can be concluded 
that D1 of GFRα1 does not participate 
in interactions with RET. However, 
according to our results D1 stabilises the 
GDNF/GFRα1 complex and thus affects 
the phosphorylation of RET. What the 
mechanism of this stabilisation is, is still 
unclear, because the published structures 
of GFRα1 (IV) and GFRα3 (Wang et al., 
2006) both lack the D1. However, in our 
gel fi ltration chromatography studies, both 
the full-length and the truncated soluble 
GFRα1s were eluted as monomers, which 
makes direct D1-D1 contacts unlikely. 
Hence an interaction between D1 and 
GDNF seems more likely. However, since 
the difference in GDNF-binding between 
the truncated and full-length GFRα1 
proteins only accounts for much less than 
one hydrogen bond, it is possible that 
instead of having a direct contact with 
GDNF, D1 actually has an effect on the 
conformation of domains 2 and 3.
In their studies, Scott and Ibáñez 
(2001) had found D1 dispensable for 
both ligand binding specifi city and RET 
phosphorylation. In their work, the 
truncated GFRα1 lacking D1 binds GDNF 
and there is no significant difference in 
RET phosphorylation in the presence of 
full-length GFRα1 and GFRα1 lacking 
D1. However, their phosphorylation assays 
were done in Neuro 2a cells and thus in 
the presence of endogenous GFRα1, 
which may have masked the difference. 
Moreover, our finding that the high 
expression levels of GPI-anchored GFRα1 
receptors indeed mask the impaired 
function of the truncated receptors might 
also explain why this study failed to show 
differences for full-length and truncated 
GFRα1 receptors. We also speculate that, 
at high concentrations of GDNF, a similar 
effect might occur: most GFRα1 receptors 
will become saturated in spite of their 
slightly weaker capacity to bind GDNF.
Taken together, D1 has a small, but 
clear stabilising effect for the function 
of GFRα1. This effect may be important 
in physiological conditions, where the 
concentration of the ligand or the soluble 
GFRα1 receptor is low. The spreading 
of GDNF in tissues has been shown to 
be very limited and a major problem 
in therapeutic approaches (Hamilton et 
al., 2001). Due to the poor spreading in 
tissues, the concentrations of GDNF, even 
at a short distance from the injection site, 
can be very low. Therefore, our fi ndings 
may become useful in designing and 
considering the use of new therapeutic 
molecules.
It is possible that D1 has also other, 
unidentifi ed functions. In our later study 
(IV), full-length GFRα1 was found to 
bind heparin more strongly than GFRα1 
that lacks D1. This result needs to be 
confi rmed, but it may suggest a role for D1 
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in the distribution of putatively released 
GFRα1, formation of the GFL/GFRα/RET 
complex or cell adhesion-related functions 
of GFRα receptors, proposed by Ledda et 
al. (2007). Results of further studies, such 
as complete structures of GFL/GFRα/RET 
complexes, will probably enlighten these 
possibilities.
Activity of RET3. MEN 2B in the 
endoplasmic reticulum (III)
As mentioned previously, in most cell 
types RET proteins are expressed as 
glycoproteins of 150 and 170 kDa, which 
differ in their subcellular localisation. 
The 170 kDa isoform of RET is present 
at the plasma membrane, whereas the 
incompletely processed 150 kDa form of 
RET is present in the ER (van Weering et 
al., 1998). In this work, we characterised 
the activation of RETMEN 2B precursor in 
the endoplasmic reticulum. The RETMEN 
2B mutant that was used has the kinase 
domain point mutation M918T, which is 
the most common mutation in MEN 2B 
(Mulligan and Ponder, 1995).
Technical concerns related to 3.1 
RET activation
Studying the intracellular activation of 
RET precursors has been technically 
challenging because mutations that 
impair the maturation of RET, and thus 
prevent its transportation to the cell 
surface, have initially been reported to 
decrease its kinase activity (Chappuis-
Flament et al., 1998). For this reason, we 
fi rst used Brefeldin A to trap RET in the 
ER.  Brefeldin A disrupts the function of 
the intermediate compartment and Golgi 
apparatus and thus jams the secretory 
proteins in the ER. 
Another obstacle in studying any 
RET activation is that a long-term 
overexpression of RET leads to its auto-
phosphorylation (III, Figure 1A). In many 
cases, this background phosphorylation is 
so strong that the detection of the ligand-
induced phosphorylation can be very 
diffi cult, or even impossible. To overcome 
this problem, we transfected the cells 
transiently with RET/GFRα1 and kept 
the expression time short. By taking early 
time course samples, we could follow 
the production and phosphorylation of 
RETWT and RETMEN 2B and see that the 
150 kDa form of both RET variants is 
phosphorylated already at very early 
stages (III, Figure 1B). In addition, the 
background phosphorylation of RET is 
already at 8 h after the transfection so 
strong that monitoring ligand-induced 
phosphorylation is very diffi cult. Therefore, 
we used 8 h or shorter expression time 
in most experiments. However, in some 
experiments, we used phosphotyrosine 
specific antibodies that recognised only 
high levels of phosphorylated RET, and 
thus higher overexpression was necessary 
in those particular experiments.
Localisation and 3.2 
phosphorylation of RET 
precursor
We transfected transiently PC6-3 cells 
with different RET variants and then 
expressed these proteins in the presence 
of Brefeldin A. Only the 150 kDa form of 
all the kinase active RET variants can be 
seen in the Western blots made of these 
samples, which confirms that the 150 
kDa form of RET is located in the ER 
(III, Figure 1C). In the case of RETWT, 
RETMEN 2A and RETMEN 2B, this 150 kDa 
precursor form is also phosphorylated. 
The kinase-dead MEN 2A form of RET 
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(double mutation C634R/E921K, Pelet et 
al. 1998) is, however, not phosphorylated, 
which indicates that the activation of the 
precursor is dependent on its own kinase 
domain. The activity is also not dependent 
on GFRα1 because GFRα1 was not present 
in this experiment.
With the help of antibodies that 
specifically recognise phosphorylated 
tyrosines of RET, it has been shown that 
residues 905, 1015, 1062 and 1096 get 
phosphorylated upon GDNF-stimulation 
in the mature 170 kDa form of RET 
(Tsui-Pierchala et al., 2002a). We used 
these same antibodies to study whether 
the phosphorylation pattern in the 
precursor form of RETMEN 2B is similar to 
that of the precursor and mature form of 
RETWT. Although the ligand-independent 
phosphorylation of RET was high due 
to the overexpression of RET, we could 
see that in the mature form of RETWT 
GDNF caused a clear phosphorylation of 
Tyr905, Tyr1062 and Tyr1096 (III, Figure 
1D). The signal detected by the antibody 
against the phosphorylated Tyr1015 was 
so weak that we could not detect RET 
phosphorylation and therefore the data are 
not included. The precursor of RETWT was 
also phosphorylated at Tyr905, Tyr1062 
and Tyr1096. However, in the precursor, 
as well as in the mature form of oncogenic 
RETMEN 2B, the phosphorylation at these 
tyrosines was much stronger than in 
RETWT.
Interactions between RET3.3 MEN 2B 
precursor and adapter proteins 
SHC and GRB2 in the ER
It has been shown that the docking of 
SHC to the phosphorylated Tyr1062 
in RET is crucial for the transforming 
activity of activated oncogenic RET 
(Ishiguro et al., 1999) and important for 
the pathogenic function of RET in MEN 
2B (Salvatore et al., 2001). To study 
whether the precursor of RETMEN 2B can 
also recruit SHC to the ER, we used two 
kinds of co-immunoprecipitations: In one 
experiment, we immunoprecipitated SHC 
and then detected by Western blotting with 
RET antibodies whether the precursor 
forms of RETWT and RETMEN 2B were also 
precipitated. In another experiment, we 
expressed RETWT and RETMEN 2B in the 
presence of Brefeldin A to keep all RET 
in the precursor form. RET was then 
immunoprecipitated and the presence of 
SHC in the precipitate was detected by 
Western blotting with antibodies to SHC. 
The results of the fi rst experiment showed 
that RETMEN 2B was more phosphorylated 
and its precursor recruited more SHC 
than the precursor of RETWT (III, Figure 
2A). The results of the latter experiment 
confi rmed that the precursor of RETMEN 2B 
and SHC were associated (III, Figure 2B). 
The latter assay was done in the absence 
of GFRα1, so the results also proved that 
the interaction of RETMEN 2B precursor and 
SHC does not depend on GFRα1.
Brefeldin A, which had been so 
far used to trap RET after its synthesis 
in the ER disrupts the function of the 
intermediate compartment and Golgi. 
Conditions where Brefeldin A is present 
are thus unnatural for the cell, and it can 
be speculated that the addition of Brefeldin 
A could affect some of the signalling 
pathways. Therefore, we wanted to use 
another approach to further characterise 
the binding of adapter proteins to RETMEN 
2B precursors. In addition to the kinase-
dead mutant (RETE921K), we made two 
other mutant forms of RET (characterised 
in Carlomagno et al., 1996). Of these 
mutants RETMEN 2B/S32L was previously 
reported to have a severely impaired 
transport to the cell surface, while the 
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RETMEN 2B/F393L mutant was reported to be 
less severely affected (Carlomagno et al., 
1996). However, in our experiments, the 
170 kDa mature form of neither mutant 
was detectable. In contrast to the original 
report (Carlomagno et al., 1996), the 
kinase activity of the 150 kDa form was 
comparable to that of RETMEN 2B.
With these mutants, we set out to 
study the binding of GRB2 and found that 
the precursors of RETWT and RETMEN 2B are 
indeed associated with GRB2 (III, Figure 
2D). In the same experiment, we also 
confi rmed the SHC association with RET 
precursors (III, Figure 2C). Both GRB2 
and SHC associations were shown to be 
dependent on the kinase activity of RET, 
since this association did not happen with 
the kinase-dead RET variant.
Downstream signalling mediated 3.4 
by RETMEN 2B precursor in the ER
To character ise  the  downstream 
signalling possibly caused by the bound 
adapter proteins, we chose to study the 
activation of three proteins participating 
in the signalling mediated by RET. 
The AKT pathway activation has been 
linked with strong phosphorylation in 
Tyr1062 (Salvatore et al., 2001) and we 
had shown that Tyr905, Tyr1062 and 
Tyr1096 are phosphorylated already in 
the precursor of RETMEN 2B. In addition, 
we had shown that SHC that binds to 
phosphorylated Tyr 1062 and GRB2 
that binds to phosphorylated Tyr1096 
were phosphorylated by the precursor of 
RETMEN 2B. Because the activation of SHC 
and GRB2 leads to activation of PI3K/
AKT, we wanted to know whether also 
AKT becomes activated.
In the AKT phosphorylation assay, we 
used a short transient transfection of RET. 
However, our first results showed that 
the transfection reagent Lipofectamine 
2000 (Invitrogen) induced a clear 
phosphorylation of AKT (III, Figure 3A), 
and therefore, we had to use a different 
transfection method based on a magnet 
assisted system, which did not cause AKT 
activation in our experiments. To trap RET 
in the ER, we used Brefeldin A. The results 
of this assay showed that the expression 
of the precursors of RETWT and RETMEN 2B 
leads to AKT phosphorylation, although 
the phosphorylation was somewhat 
stronger in the absence of Brefeldin 
A, when some of the RET synthesised 
matures into the 170 kDa form (III, Figure 
3B).
For further characterisation of 
the AKT activation and the other two 
signalling proteins STAT3 and ERK, we 
used the ER-retaining mutants RETMEN 
2B/S32L and RETMEN 2B/F393L. With transient 
transfection and expression of RET 
variants, we showed that in addition to 
AKT, also ERK and STAT3 become 
activated by the 150 kDa precursor forms 
of RETMEN 2B and that the activation is 
dependent on the RET kinase activity (III, 
Figure 4).
The precursor of RET3.5 MEN 2B is 
biologically active
In  spi te  of  the  re la t ively  good 
documentation of RET synthesis and 
maturation (van Weering et al., 1998), 
very little has been known on the activity 
of RET precursors. Miyazaki et al. (1993) 
have demonstrated that in vitro RET 
precursor (150 kDa form) can get even 
more strongly phosphorylated than the 
mature RET (170 kDa form). However, in 
several cell line experiments (e.g. Asai et 
al., 1995, Carlomagno et al., 1996, Frêche 
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et al., 2005), the 170 kDa form is more 
phosphorylated than the 150 kDa form, 
although the results of Carlomagno et al. 
(1996) are not completely consistent, and 
can be interpreted also differently from 
the authors’ conclusions. In Carlomagno 
et al. (1996), the abundance of RET 150 
kDa and 170 kDa forms also clearly 
differs from our observations, which is 
probably due to different cell types and 
different transfection methods. Asai et al. 
(1995) could not detect dimerisation of 
the 150 kDa RETMEN 2A protein, and they 
found that the transport of the RETMEN 2A 
protein to the plasma membrane and thus 
the maturation of RETMEN 2A is required for 
its transforming activity.
Taken together, our results show that 
the precursor of RETMEN 2B associates with 
SHC and GRB2 and has the capacity to 
activate downstream signalling molecules 
AKT, ERK and STAT3 in the ER. This 
result is well consistent with the fi ndings 
that the intracellularly located PTC form 
of RET can activate AKT (Miyagi at al., 
2004), ERK (Knauf et al., 2003) and 
STAT3 (Hwang et al., 2003), although 
it never reaches the cell surface. It has 
also been shown that EGF receptors form 
dimers in the absence of a bound ligand 
and this dimerisation occurs probably 
already in the endoplasmic reticulum 
(Tao and Maruyama, 2008), but also 
contradictory results have been published 
(Ferguson et al., 2003). Either way, the 
activity of the preformed dimers in the ER 
was not studied by Tao and Maruyama.
However, some plasma membrane 
RTKs can signal from different cellular 
compartments. It has been reported that 
RET that has been internalised after the 
ligand-induced activation can activate 
of ERK1/2 (Richardson et al., 2006). 
EGFR cannot activate MAPK (mitogen-
activated protein kinase) signalling until it 
has been internalised (Vieira et al., 1996). 
Moreover, internalised TrkA receptors 
induce activation of many signalling 
pathways, in particular ERK1/2 and PI3K 
pathways (Heerssen and Segal, 2002). A 
mutated FGFR3 (fi broblast growth factor 
receptor 3) has been found to accumulate 
in its immature and phosphorylated form 
in the ER, where it also signals (Lievens 
et al., 2004). A mutant form of FLT-3 
(Fms-like tyrosine kinase receptor 3) has 
an impaired maturation and transport 
to the cell surface, which seems to be 
caused by its constitutive kinase activity. 
Inhibition of this activity promotes cell 
surface localisation and, on the other 
hand, general phosphatase inhibition 
impairs the maturation of wild-type FLT-3 
(Schmidt-Arras et al., 2005). This kind 
of accumulation or delayed cell surface 
expression of oncogenic RET was not 
found in our experiments, but otherwise 
our results are consistent with these earlier 
fi ndings.
Our finding that the oncogenic 
precursor of RETMEN 2B is active in the ER 
may be signifi cant in the development for 
methods to inhibit the activity of oncogenic 
RET because it shows that the inhibition 
should reach not only the mature form of 
RET, which is located on the cell surface, 
but also the intracellular precursor form 
RET. Therefore, some of the various kinds 
of therapeutic approaches suggested for 
the treatment of RET-associated cancers 
(discussed in Kodama et al., 2005), for 
example using RET dimerisation inhibitors 
or blocking antibodies that affect RET 
only extracellularly, may not be suffi cient 
alone, but need to be complemented by 
approaches that can affect the activity of 
intracellular RET.
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Structure of the GDNF-GFRα1 4. 
complex (IV)
The structure of the GFRα1 domains 2 and 
3 (GFRα1 D23C) in complex with GDNF 
was solved with X-ray crystallography 
by molecular replacement and refi ned to 
Rwork 18.4 % (Rfree 23.7) (IV, Table 1). The 
structure contains residues 150-349 of 
GFRα1 and residues 34-134 of GDNF.
GDNF-GFRα1-SOS complex4.1 
The structure of the domains 2 and 3 of 
GFRα1 resemble each other closely: both 
consist of five α helices of which three 
helices form a spiral (IV, Figure 2A). 
These domains pack so that D3 stabilises 
D2. Each GDNF monomer in the GDNF2-
GFRα12 structure binds GFRα1 D2 with its 
fi nger domains 1 and 2 (numbering starts 
from the N-terminal part). The binding site 
in GFRα1 is located in the triangular spiral 
formed by the helices α1, α2 and α5 of the 
domain 2. 14 residues from GDNF and 17 
residues from GFRα1 form the interface 
(IV, Table 2; Review of the literature, 
Figure 1), which buries a total surface 
area of about 1600 Å2. N162GFRα1 stabilises 
a central ion triple R171GFRα1 – E61GDNF 
– R224GFRα1 by positioning R171GFRα1 
guanidine group and forming hydrogen 
bonds to E61GDNF, E62GDNF and S112GDNF 
(IV, Figure 2C). Hydrophobic interactions 
are formed between Y120GDNF –I175GFRα1 
– L114GDNF and I175GFRα1 – I122GDNF – 
T176GFRα1. Two ionic interactions at the 
edge of the GDNF-GFRα1 interface are 
formed between E62GDNF – K159GFRα1 and 
K168GFRα1 – D108GDNF– D109GFRα1.
Previously, Eketjäll et al. (1999) had 
mapped GDNF residues that participate 
in GFRα1 binding by mutating GDNF 
residues and testing the mutants in GDNF-
GFRα1 binding assays. In this study, they 
found several negatively charged and 
hydrophobic residues that are critical for 
GFRα1 binding. Our structure is well in 
line with their results: at least six GDNF 
residues that they suggested to be involved 
in GFRα1 binding are found in the core 
region of GDNF-GFRα1 interface. Of 
these, E61, E62 and I64 are located in the 
tip of fi nger 1 of GDNF whereas L114, 
Y120 and I122 are located in fi nger 2.
Two carbohydrates can be seen in 
the structure: one N-acetylglucosamine 
molecule is covalently linked to N49GDNF 
and a sucrose octasulfate molecule (SOS, 
a heparin analogue) binds to D2 and 
D3 of GFRα1 (IV, Figures 2A and 3A). 
According to the structure, the sulphate 
groups of the SOS molecule bind to fi ve 
residues on GFRα1 D2 and three residues 
on D3. Through a crystal contact, the same 
SOS molecule also binds to the N-terminus 
of the GDNF of the neighbouring 
complex.
Interactions between GDNF, 4.2 
GFRα1, SOS and RET
To demonstrate that the residues found 
in the GDNF-GFRα1 and SOS-GFRα1 
interfaces in the structure are really 
involved in GDNF and SOS binding, 
and to understand which residues in the 
GDNF-GFRα1 interface are important for 
specifi city, a series of mutants was tested in 
RET phosphorylation assays. In addition, 
we wanted to study experimentally 
whether the conserved GFRα1 residues 
(D164, K202, R257, R259, E323 and 
E324, GFRα1 numbering) proposed by 
Wang et al. (2006) are really involved in 
RET binding. The mutants can be thus 
divided into three categories: 1) mutants 
in the GDNF-GFRα1 interface, 2) mutants 
in the SOS binding region and 3) mutants 
in the putative RET-binding region. The 
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latter two regions were expected to overlap 
at least partly. In addition, we tested two 
other mutants that had shown differences 
in GDNF-binding or RET phosphorylation 
in earlier studies (Leppänen et al., 2004)
The RET phosphorylation assays in 
MG87RET cells and subsequent pRET 
ELISAs showed that the mutations in 
N162, which stabilises the GDNF-GFRα1 
interface central ion triple, and I175, which 
is part of the hydrophobic core, caused 
drastic reduction in RET phosphorylation 
(IV, Figure 1B). Mutations in more 
peripheral residues in this interface 
reduced RET phosphorylation less. The 
binding studies with SPA supported these 
results.
Mutations in the residues expected 
to be on the RET/SOS binding surface of 
GFRα1 all reduced the phosphorylation of 
RET about by a factor of three or more, 
except for D164A, which only lowered the 
amount of RET phosphorylation to about 
half of wild-type (IV, Figure 1B and table 
3). Binding studies were also consistent 
with these results. Thus, all of these 
residues in GFRα1 are likely to participate 
in forming the RET interface.
Comparison of GDNF-GFRα1 to 4.3 
ARTN-GFRα3
Comparison of the structure of the 
GDNF-GFRα1 complex and the recently 
published (Wang et al., 2006) structure 
of ARTN-GFRα3 complex reveals 
similarities, as well as differences (IV, 
Figures 2A and 2B). The overall structures 
of the receptors are very similar (root 
mean square deviation of 0.89 Å for 166 
Cα atoms). In addition, both GFLs reach 
their fingers to the triangular spiral of 
GFRα (formed by the helices α1, α2 and 
α5 of the domain 2) and the centre of this 
interface contains the above mentioned ion 
triple (IV, Figure 4A).
However, there are three important 
differences. The fi nger loops of the ARTN 
and GDNF are inclined differently in 
relation to the heel region, so that when 
the heel regions of GDNF and ARTN are 
superimposed, the angle between the fi nger 
loops is about 20 ° (IV, Figure 4C). The 
position of the ligand fi ngers in relation 
to the GFRα interface is also different: in 
comparison to GDNF, the fi nger loops of 
ARTN twist about their longitudinal axis 
and turn around a vertical axis in relation 
to the GFRα binding site so that the angle 
difference is about 20 ° (IV, Figure 4A).
The third significant difference is 
seen in the core region of the GFL-GFRα 
interface (IV, Figure 4B). N162, which 
buttresses the ion triple in GDNF-GFRα1 
complex, does not have a counterpart 
in GFRα3: the equivalent GFRα3 T170 
does not interact with the ion triple. The 
ARTN binding pocket in GFRα3 is also 
much wider and less deep than the GDNF 
binding pocket in GFRα1, since it contains 
G in comparison to GFRα1 I175 and A in 
comparison to GFRα1 V230. The W205 
and M199 from ARTN fit thus in the 
GFRα3 pocket as well as the Y120 and 
L114 in the GFRα1 pocket.
These differences in the binding 
pocket are important for the ligand 
specifi city, whereas the differences in the 
angles between the GFL fi nger loop and 
the heel region, and between the GFL 
and the GFRα ligand binding site affect 
the quaternary structures of the whole 
GFL-GFRα complex. The different bend 
angles can change the conformation of 
the intracellular part of RET, causing 
alterations in the adaptor protein docking 
surfaces. This could putatively lead to 
different signalling through RET by 
different GFLs, although overall RET 
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phosphorylation level would not be 
changed.
To investigate this hypothesis, we 
set up to study differences in downstream 
signalling of RET induced by GDNF-
GFRα1 and ARTN-GFRα3. According to 
our results, GDNF causes stronger and 
faster MAPK pathway activation than 
ARTN (IV, Figure 4D). However, this does 
not give direct evidence of differences in 
RET conformation or phosphorylation of 
docking surfaces. Therefore, more studies 
are needed to confi rm the hypothesis. To 
study the detailed phosphorylation pattern 
of RET after stimulation with different 
ligands, I have recently managed to set up 
a method to purify endogenous RET from 
mammalian cells after ligand stimulation. 
After digestion of RET with trypsin, 
the phosphorylated peptides will be 
subjected to mass-spectrometry analysis, 
as has recently been done with EGFR 
(Boeri Erba et al., 2005). Results of these 
experiments are expected to shed light on 
the differences in phosphorylation and 
downstream signalling of RET induced by 
different GFLs.
Role of heparin in the GDNF-4.4 
GFRα1-RET complex
Our work gives some insight into how 
heparin might inhibit RET phosphorylation, 
even when the heparin-binding region of 
GDNF has been removed. In our structure, 
we could see a SOS molecule (heparin 
analogue added prior to the purifi cation) 
bound to GFRα1 (IV, Figure 3A). The 
region which binds SOS in our structure 
overlaps partially with the RET-binding 
region of GFRα1 (IV, Figures 3A and 
3D). Since a heparin molecule could fi t 
in the same position as SOS (IV, Figure 
5), it seems that heparin could indeed bind 
to this region and prevent the binding of 
RET.
Our model also gives a possible 
explanation to how GDNF-GFRα1 
complex could work in adhesion and 
induce synapse formation, as suggested 
by Ledda et al. (2007). In our structure, 
SOS links a GDNF2-GFRα12 complex 
to a neighbouring complex. We can thus 
speculate that heparin might mediate 
this kind of dimerisation of the GDNF2-
GFRα12 complexes as well as NRTN2-
GFRα22 complexes.
However, although SOS can be seen 
in the structure, it can be speculated that 
binding is not specific; as a strongly 
negatively charged molecule SOS might 
bind to a positively charged surface of 
GFRα1 unspecifi cally. In our experiments 
where heparin binding of GFRα1 was 
studied, the full-length GFRα1 eluted from 
the heparin column at a very high (>1 M) 
NaCl concentration, which indicates strong 
binding. The GFRα1 D23C that was used 
in the crystallisation eluted at about half of 
this concentration, which suggests reduced 
but still strong binding. Yet Alfano et al. 
(2007) have found that GFRα1 itself does 
not bind heparin. They postulate that 
the heparin binding of the commercial 
recombinant chimeric GFRα1 protein 
(R&D Systems Europe) can be caused by 
the His-tag (Lacy and Sanderson, 2002). 
Since we also had a His-tag in our GFRα1 
construct used for heparin-binding studies, 
we cannot exclude the possibility that the 
observed binding was unspecifi c. Although 
the GFRα1 used in the crystal structure 
was untagged, the interaction of SOS and 
GFRα1 in the crystal may not be specifi c. 
Therefore, the results of SOS/heparin 
binding to GFRα1 in this study should be 
considered preliminary.
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CONCLUSIONS
The aim of this thesis was to study the 
structure of GFRα1 and the localisation 
and site of activation of both GFRα4 and 
RET. We found that PSPN/GFRα4 is not 
associated with lipid rafts as tightly as 
GDNF/GFRα1, and does not recruit RET 
to lipid rafts as efficiently as GDNF/
GFRα1 (I). This might be due to the lack 
of domain 1 in GFRα4 as domain 1 in 
GFRα1 seems to stabilise the binding of 
GDNF to GFRα1 and thus to strengthen 
the GDNF-GFRα1-RET complex (II). 
In addition to the stabilisation of GDNF 
binding to GFRα1, we found that domain 
1 may contribute to the heparin-binding 
of GFRα1 (IV). As our heparin-binding 
studies give only preliminary information, 
further studies are needed to confi rm this 
function for GFRα1 domain1.
In addition to studying in which 
compartment of the cell membrane RETWT 
is activated, we studied in which cellular 
compartment the oncogenic RETMEN 2B 
gets activated. We found that RETMEN 2B 
gets activated and signals in the ER (III). 
This is consistent with our conclusion 
that localisation on the lipid rafts is not 
necessary for the signalling and biological 
activity of RET (I). Further studies on 
the interactions between different GFRα 
receptors and RET may shed light on 
the mechanism and significance of 
RET recruitment to the lipid rafts. More 
detailed studies on RET signalling in 
different compartments of the cell may 
also reveal interesting information of 
the signifi cance of the localisation of the 
signalling complex.
The main conclusions are:
The mouse GFRα4 is less tightly I. 
associated with the Triton X-100 
insoluble fraction than GFRα1. It also 
recruits RET upon ligand stimulation 
to lipid rafts more weakly than GFRα1. 
However, mouse GFRα4 can mediate 
PSPN-dependent differentiation and 
survival of neurons.
The first cysteine-rich domain of II. 
GFRα1 stabilises the binding of 
GDNF to GFRα1. It affects the 
level of RET phosphorylation at 
low concentrations of GFRα1 and 
contributes to the biological activity.
The precursor of oncogenic RETIII. MEN 2B 
is active in the endoplasmic reticulum. 
It associates with adaptor proteins 
SHC and GRB2 and has the capacity 
to activate downstream signalling 
molecules AKT, ERK and STAT3 in 
the endoplasmic reticulum.
The crystallographic structure of IV. 
GFRα1 domains 2 and 3 in the 
complex with GDNF differs from 
ARTN-GFRα3 structure in three 
signifi cant ways: 1) The fi nger loops 
of ARTN and GDNF are inclined 
differently in relation to the heel 
region. 2) The position of the ligand 
fingers in relation to the GFRα 
interface is different. 3) The residues 
in the GDNF-GFRα1 interface form 
interactions different from the residues 
in the ARTN-GFRα3 interface.
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